{"content":"<li class=\"n-box-item date-title\" data-end=\"1554177599\" data-start=\"1554091200\" data-txt=\"Monday, December 23, 2019\">Monday, April  1, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3447582\" data-ts=\"1554174484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTNB\" target=\"_blank\">MTNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447582-matinas-biopharma-holdings-misses-0_02\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matinas Biopharma Holdings misses by $0.02</a></h4><ul><li>Matinas Biopharma Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>): FY GAAP EPS of -$0.15 <span style=\"color:red\">misses by $0.02</span>.</li><li>Revenue of $0.12M (-20.0% Y/Y)</li><li>Shares <font color=\"green\">+3%</font> AH.</li><li><a href=\"https://seekingalpha.com/filing/4428058\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447582\" data-linked=\"Matinas Biopharma Holdings misses by $0.02\" data-tweet=\"$MTNB - Matinas Biopharma Holdings misses by $0.02 https://seekingalpha.com/news/3447582-matinas-biopharma-holdings-misses-0_02?source=tweet\" data-url=\"https://seekingalpha.com/news/3447582-matinas-biopharma-holdings-misses-0_02\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447577\" data-ts=\"1554166538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZEAL\" target=\"_blank\">ZEAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447577-zealand-pharma-files-for-200m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zealand Pharma files for $200M equity offering</a></h4><ul><li>Zealand Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ZEAL' title='Zealand Pharma A/S'>ZEAL</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1674988/000110465919018963/a19-7188_1f3.htm\" target=\"_blank\">prospectus </a>for a $200M public offering of ordinary shares, including ordinary shares represented by its ADSs. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447577\" data-linked=\"Zealand Pharma files for $200M equity offering\" data-tweet=\"$ZEAL - Zealand Pharma files for $200M equity offering https://seekingalpha.com/news/3447577-zealand-pharma-files-for-200m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3447577-zealand-pharma-files-for-200m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447569\" data-ts=\"1554158402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447569-sangamominus-2_9-sets-tuesday-clinical-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo -2.9% as it sets Tuesday clinical update</a></h4><ul>   <li>Shares in Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) are <font color=\"red\">2.9% lower</font> postmarket after the company announced a <a href=\"https://seekingalpha.com/pr/17462153-sangamo-therapeutics-host-april-2-2019-conference-call-provide-clinical-update\" target=\"_blank\">call for tomorrow with a clinical update</a>.</li>    <li>The <a href=\"https://edge.media-server.com/m6/p/ks5yxvb4\" target=\"_blank\">call's set for 8 a.m. ET</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447569\" data-linked=\"Sangamo -2.9% as it sets Tuesday clinical update\" data-tweet=\"$SGMO - Sangamo -2.9% as it sets Tuesday clinical update https://seekingalpha.com/news/3447569-sangamominus-2_9-sets-tuesday-clinical-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3447569-sangamominus-2_9-sets-tuesday-clinical-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447567\" data-ts=\"1554157094\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447567-aveoplus-22_5-after-positive-results-from-aml-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO +22.5% after positive results from AML trial</a></h4><ul>   <li>AVEO Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) is <font color=\"green\">up 22.5%</font> on heavy volume after hours following positive results from a trial addressing acute myeloid leukemia.</li>    <li>Along with Biodesix, the company said at the American Association for Cancer Research that a combination of ficlatuzumab and cytarabine showed attractive tolerability in patients with relapsed and refractory AML.</li>    <li>The Phase IB trial was funded by Gateway for Cancer Research.</li>    <li>\u201cPatients with AML who are refractory to induction therapy or relapse within one year have poor outcomes,\u201d said Dr. Charalambos Andreadis, director of the trial. \u201cElevated serum HGF level is an adverse prognostic factor, and these results demonstrate that the anti-HGF antibody ficlatuzumab combined with cytarabine holds potential to affect outcomes in patients with relapsed or refractory AML.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447567\" data-linked=\"AVEO +22.5% after positive results from AML trial\" data-tweet=\"$AVEO - AVEO +22.5% after positive results from AML trial https://seekingalpha.com/news/3447567-aveoplus-22_5-after-positive-results-from-aml-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3447567-aveoplus-22_5-after-positive-results-from-aml-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447560\" data-ts=\"1554155988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BILI\" target=\"_blank\">BILI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447560-bilibiliminus-1_9-amid-ads-offering-convertible-notes-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bilibili -1.9% amid ADS offering, convertible notes offering</a></h4><ul>   <li>Bilibili (NASDAQ:<a href='https://seekingalpha.com/symbol/BILI' title='Bilibili Inc.'>BILI</a>) is <font color=\"red\">1.9% lower</font> in postmarket trading after proposing an offering of <a href=\"https://seekingalpha.com/pr/17462238-bilibili-inc-announces-proposed-offering-10554-000-american-depositary-shares\" target=\"_blank\">just over 10.55M of its American Depositary Shares</a>.</li>    <li>It also announced an offering of <a href=\"https://seekingalpha.com/pr/17462233-bilibili-inc-announces-proposed-offering-us-300-million-convertible-senior-notes\" target=\"_blank\">$300M in convertible senior notes</a> due 2026.</li>    <li>Underwriters in the ADS offering will get a 30-day option to buy up to an additional 2,562,028 ADS. Initial purchasers in the notes offering will geot an option to buy up to an additional $45M in notes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447560\" data-linked=\"Bilibili -1.9% amid ADS offering, convertible notes offering\" data-tweet=\"$BILI - Bilibili -1.9% amid ADS offering, convertible notes offering https://seekingalpha.com/news/3447560-bilibiliminus-1_9-amid-ads-offering-convertible-notes-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3447560-bilibiliminus-1_9-amid-ads-offering-convertible-notes-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447550\" data-ts=\"1554154525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447550-tlrd-edap-apyx-and-pfnx-among-notable-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TLRD, EDAP, APYX and PFNX among notable after hours movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a> <font color=\"green\">+47.22%</font>. <a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a> <font color=\"green\">+10.37%</font>. <a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a> <font color=\"green\">+8.15%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color=\"green\">+6.60%</font>. <a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a> <font color=\"green\">+5.00%</font>.<strong> </strong></li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/APYX' title='Apyx Medical Corporation'>APYX</a> <font color=\"red\">-42.45%</font>. <a href='https://seekingalpha.com/symbol/PFNX' title='Pfenex Inc.'>PFNX</a> <font color=\"red\">-13.66%</font>. <a href='https://seekingalpha.com/symbol/NCZ' title='AllianzGI Convertible&Income Fund II'>NCZ</a> <font color=\"red\">-7.79%</font>. <a href='https://seekingalpha.com/symbol/OCX' title='OncoCyte Corporation'>OCX</a> <font color=\"red\">-7.06%</font>. <a href='https://seekingalpha.com/symbol/NCV' title='AllianzGI Convertible&Income Fund'>NCV</a> <font color=\"red\">-7.02%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447550\" data-linked=\"TLRD, EDAP, APYX and PFNX among notable after hours movers\" data-tweet=\"$TLRD $EDAP $MXC - TLRD, EDAP, APYX and PFNX among notable after hours movers https://seekingalpha.com/news/3447550-tlrd-edap-apyx-and-pfnx-among-notable-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447550-tlrd-edap-apyx-and-pfnx-among-notable-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447543\" data-ts=\"1554153489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447543-ocular-therapeutixminus-2_5-holders-file-to-sell-9_57m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular Therapeutix -2.5% as holders file to sell 9.57M shares</a></h4><ul>   <li>Ocular Therapeutix (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix, Inc.'>OCUL</a>) is <font color=\"red\">2.5% lower</font> postmarket after shareholders <a href=\"https://seekingalpha.com/filing/4427838\" target=\"_blank\">filed to offer 9.57M shares</a>.</li>    <li>That filing proposes a maximum offering price of $3.94 each; shares closed today at $4.07.</li>    <li>Of the 9.57M shares covered in the filing, 5.77M are issuable on the conversion of a senior subordinated convertible note between the company and an affiliate of Summer Road LLC, and 3.8M shares held by Summer Road affiliates.</li>    <li>The selling stockholders are Cap 1 LLC (which has an 18.4% stake, and would exit its position) and East River Partners (with a 1.5% stake, and also would exit its position).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447543\" data-linked=\"Ocular Therapeutix -2.5% as holders file to sell 9.57M shares\" data-tweet=\"$OCUL - Ocular Therapeutix -2.5% as holders file to sell 9.57M shares https://seekingalpha.com/news/3447543-ocular-therapeutixminus-2_5-holders-file-to-sell-9_57m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3447543-ocular-therapeutixminus-2_5-holders-file-to-sell-9_57m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447511\" data-ts=\"1554151224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MARK\" target=\"_blank\">MARK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447511-remark-holdingsminus-4_6-after-q4-revenues-fall-short\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Remark Holdings -4.6% after Q4 revenues fall short</a></h4><ul>   <li>Remark Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a>) is <font color=\"red\">4.6% lower</font> after hours following a miss on Q4 revenues, which came in even below preliminary numbers announced in January.</li>    <li>Revenues rose to $22.3M, up nearly 20%, but fell short of its earlier guidance for $26.6M-$26.8M.</li>    <li>Revenues rose by $4M in transaction growth in Travel &amp; Entertainment, offset by a $0.3M drop in other business units.</li>    <li>Net loss shrank to $7.1M from a year-ago loss of $89.2M; this year included a noncash gain of $5.7M vs. last year's $66.5M noncash loss due to a change in warrant liability.</li>    <li>And adjusted EBITDA fell to -$4.6M from -$2.2M.</li>    <li>Cash and equivalents at year-end was $14.4M, and restricted cash was $11.1M; the combined total of $25.5M was down from the prior-year $34.3M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447485-remark-holdings-beats-0_32-misses-revenue\" target=\"_blank\">Remark Holdings beats by $0.32, misses on revenue</a> (Apr. 01 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17462072-remark-holdings-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3447511\" data-linked=\"Remark Holdings -4.6% after Q4 revenues fall short\" data-tweet=\"$MARK - Remark Holdings -4.6% after Q4 revenues fall short https://seekingalpha.com/news/3447511-remark-holdingsminus-4_6-after-q4-revenues-fall-short?source=tweet\" data-url=\"https://seekingalpha.com/news/3447511-remark-holdingsminus-4_6-after-q4-revenues-fall-short\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447509\" data-ts=\"1554151207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCDA\" target=\"_blank\">TCDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447509-tricida-files-for-stock-offering-shares-down-5-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tricida files for stock offering; shares down 5% after hours</a></h4><ul><li>Tricida (NASDAQ:<a href='https://seekingalpha.com/symbol/TCDA' title='Tricida, Inc.'>TCDA</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1595585/000162828019003724/tricidas-1.htm\" target=\"_blank\">preliminary prospectu</a>s for a public offering of 5M shares of common stock.</li><li>Shares are down <font color=\"red\">5%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447509\" data-linked=\"Tricida files for stock offering; shares down 5% after hours\" data-tweet=\"$TCDA - Tricida files for stock offering; shares down 5% after hours https://seekingalpha.com/news/3447509-tricida-files-for-stock-offering-shares-down-5-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3447509-tricida-files-for-stock-offering-shares-down-5-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447484\" data-ts=\"1554150339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPTX\" target=\"_blank\">LPTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447484-leap-therapeutics-beats-0_27\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leap Therapeutics beats by $0.27</a></h4><ul><li>Leap Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics, Inc.'>LPTX</a>): FY GAAP EPS of -$2.11 beats by $0.27.</li><li>Cash, cash equivalents and marketable securities of $16.3M.</li><li><a href=\"https://seekingalpha.com/pr/17461982-leap-therapeutics-reports-clinical-update-2018-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3447484\" data-linked=\"Leap Therapeutics beats by $0.27\" data-tweet=\"$LPTX - Leap Therapeutics beats by $0.27 https://seekingalpha.com/news/3447484-leap-therapeutics-beats-0_27?source=tweet\" data-url=\"https://seekingalpha.com/news/3447484-leap-therapeutics-beats-0_27\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447481\" data-ts=\"1554150166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APYX\" target=\"_blank\">APYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447481-apyx-down-16-after-hours-on-withdrawal-of-renuvion-application\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apyx down 16% after hours on withdrawal of Renuvion application</a></h4><ul><li>Thinly traded micro cap Apyx Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/APYX' title='Apyx Medical Corporation'>APYX</a>) is down <font color=\"red\">16% </font>after hours in reaction to its <a href=\"https://seekingalpha.com/pr/17461988-apyx-medical-corporation-provides-update-premarket-notification-510-k-submission-u-s-food\" target=\"_blank\">withdrawal </a>of its 510(k) application seeking FDA clearance for its dermal resurfacing system J-Plasma/Renuvion.</li><li>The company filed the application on December 19, 2018 despite the lack of success in its IDE study that generated the data supporting the filing.</li><li>It says it cannot provide a timeline for a resubmission at this time.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447481\" data-linked=\"Apyx down 16% after hours on withdrawal of Renuvion application\" data-tweet=\"$APYX - Apyx down 16% after hours on withdrawal of Renuvion application https://seekingalpha.com/news/3447481-apyx-down-16-after-hours-on-withdrawal-of-renuvion-application?source=tweet\" data-url=\"https://seekingalpha.com/news/3447481-apyx-down-16-after-hours-on-withdrawal-of-renuvion-application\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447466\" data-ts=\"1554149629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STAG\" target=\"_blank\">STAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447466-stag-industrialminus-2_4-after-stock-offering-starts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stag Industrial -2.4% after stock offering starts</a></h4><ul><li>Stag Industrial (NYSE:<a href='https://seekingalpha.com/symbol/STAG' title='STAG Industrial, Inc.'>STAG</a>) <font color=\"red\">slumps 2.4%</font> in after-hours trading after the launch of a<a href=\"https://seekingalpha.com/pr/17461969-stag-industrial-announces-public-offering-common-stock\" target=\"_blank\"> 6M-share public offering</a> of common stock.</li><li>Expects greenshoe option for an additional 900,000 shares of common stock.</li><li>Plans to use proceeds to repay debt outstanding under its $500M unsecured credit facility, to fund acquisitions, for working capital, and general corporate purposes or a combination of the above.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3433094-stag-q4-core-ffo-beats-1-cent-store-cash-noi-plus-0_1-percent\" target=\"_blank\">STAG Q4 core FFO beats by 1 cent, same-store cash NOI +0.1%</a> (Feb. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447466\" data-linked=\"Stag Industrial -2.4% after stock offering starts\" data-tweet=\"$STAG - Stag Industrial -2.4% after stock offering starts https://seekingalpha.com/news/3447466-stag-industrialminus-2_4-after-stock-offering-starts?source=tweet\" data-url=\"https://seekingalpha.com/news/3447466-stag-industrialminus-2_4-after-stock-offering-starts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447448\" data-ts=\"1554148526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447448-paul-jacobs-drops-qualcomm-takeover-fight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paul Jacobs drops Qualcomm takeover fight</a></h4><ul><li>Former Qualcomm (<a href='https://seekingalpha.com/symbol/QCOM' title='QUALCOMM Incorporated'>QCOM</a> <font color='green'>+1.5%</font>) CEO Paul Jacobs <a href=\"https://www.wsj.com/articles/paul-jacobs-retreats-from-qualcomm-takeover-quest-11554147331\" target=\"_blank\">retreats</a> from his takeover bid to focus on his wireless tech startup Xcom Labs.</li><li>Qualcomm <a href=\"https://seekingalpha.com/news/3340036-qualcomm-jacobs-board-meeting\" target=\"_blank\">dropped</a> Jacobs as a director last year as he fought to take the company private after President Trump blocked Broadcom's attempted takeover.</li><li>Jacobs had started gathering but decided late last year that QCOM's valuation relative to its earnings had become less attractive.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447448\" data-linked=\"Paul Jacobs drops Qualcomm takeover fight\" data-tweet=\"$QCOM - Paul Jacobs drops Qualcomm takeover fight https://seekingalpha.com/news/3447448-paul-jacobs-drops-qualcomm-takeover-fight?source=tweet\" data-url=\"https://seekingalpha.com/news/3447448-paul-jacobs-drops-qualcomm-takeover-fight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447439\" data-ts=\"1554147697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447439-whole-foods-price-cuts-on-way-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whole Foods price cuts on the way again</a></h4><ul> <li>Amazon has once again dialed up a round of <a href=\"https://www.wsj.com/articles/amazon-cuts-more-prices-at-whole-foods-11554146071\" target=\"_blank\">price cuts</a> at Whole Foods stores, according to <em>The Wall Street Journal's</em> Heather Haddon.</li> <li>Prices on more than 500 items are set to be marked lower on Wednesday at U.S. stores.</li> <li>Haddon says the price cuts are some of the broadest since Amazon's $14B acquisition of Whole Foods in 2017.</li> <li>Shares of Kroger (<a href='https://seekingalpha.com/symbol/KR' title='The Kroger Co.'>KR</a> <font color=\"green\">+0.3%</font>) and Sprouts Farmers Market (<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market, Inc.'>SFM</a> <font color=\"green\">+0.9%</font>) both dropped after the Whole Foods story hit, but are still in positive territory.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447439\" data-linked=\"Whole Foods price cuts on the way again\" data-tweet=\"$KR $SFM - Whole Foods price cuts on the way again https://seekingalpha.com/news/3447439-whole-foods-price-cuts-on-way-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3447439-whole-foods-price-cuts-on-way-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447437\" data-ts=\"1554147351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VCNX\" target=\"_blank\">VCNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447437-vaccinex-up-26-on-aacr-presentations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vaccinex up 26% on AACR presentations</a></h4><ul><li>Ultra-thinly traded Vaccinex (<a href='https://seekingalpha.com/symbol/VCNX' title='Vaccinex, Inc.'>VCNX</a> <font color=\"green\">+26%</font>) is up on over 50% higher volume, albeit on turnover of only ~13K shares, on the heels of thee <a href=\"https://seekingalpha.com/pr/17460968-vaccinex-inc-provide-clinical-data-posters-presented-2019-annual-meeting-american-association\" target=\"_blank\">presentations </a>at AACR related to its anti-SEMA4D technology.</li><li>The company states that the details of each of the three are on its website, but only the titles appear.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447437\" data-linked=\"Vaccinex up 26% on AACR presentations\" data-tweet=\"$VCNX - Vaccinex up 26% on AACR presentations https://seekingalpha.com/news/3447437-vaccinex-up-26-on-aacr-presentations?source=tweet\" data-url=\"https://seekingalpha.com/news/3447437-vaccinex-up-26-on-aacr-presentations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447422\" data-ts=\"1554145024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEAR\" target=\"_blank\">HEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447422-turtle-beachplus-4-bull-praises-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Turtle Beach +4% as bull praises sales</a></h4><ul><li>Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) bull D.A. Davidson reiterates its Buy rating and $23 PT and praises <a href=\"https://seekingalpha.com/pr/17458181-turtle-beach-achieves-historic-milestone-sells-30-million-gaming-headsets\" target=\"_blank\">recent news </a>that the company has sold more than 30M headsets since 2005.</li><li>Analyst Tom Forte says HEAR \"continues to be a market leader in the gaming headset market and has been number one by revenue for the past nine consecutive years.\"</li><li>Forte sees the potential for ASPs to increase this year due to the influx of gamers.</li><li>HEAR shares are <font color=\"green\">up 4.3%</font> to $11.85.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447422\" data-linked=\"Turtle Beach +4% as bull praises sales\" data-tweet=\"$HEAR - Turtle Beach +4% as bull praises sales https://seekingalpha.com/news/3447422-turtle-beachplus-4-bull-praises-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3447422-turtle-beachplus-4-bull-praises-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447421\" data-ts=\"1554144901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447421-valeplus-4-on-higher-iron-prices-despite-losing-certifications-asset-freeze\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale +4% on higher iron prices despite losing certifications, asset freeze</a></h4><ul><li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='green'>+3.8%</font>) shares surge to match their highest level since January's deadly dam burst after <a href=\"https://uk.reuters.com/article/uk-vale-sa-disaster/vale-shares-jump-on-iron-prices-despite-losing-certifications-asset-freeze-idUKKCN1RD29N\" target=\"_blank\">iron ore futures jumped 5.2%</a> on the Dalian Commodity Exchange to hit a seven-week high, propelled by  <a href=\"https://seekingalpha.com/news/3447098-china-factory-comeback-propels-equities\" target=\"_blank\">strong economic data from China</a> and supply concerns after Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto Group'>RIO</a> <font color='green'>+1.9%</font>) <a href=\"https://seekingalpha.com/news/3447158-rio-tinto-cuts-2019-iron-ore-output-guidance-following-cyclone-damage\" target=\"_blank\">cut  its 2019 forecast</a> for iron ore shipments.</li><li>The move happens even after a Brazilian <a href=\"https://seekingalpha.com/news/3447240-brazil-court-freezes-another-255m-vale-assets-dam-evacuation\" target=\"_blank\">court froze an additional 1B reais</a> ($255M) in  Vale assets over potential damages related to the evacuation of its Vargem  Grande dam and the company failed to obtain stability certificates for 13 dams under review - including seven tailings dams, the same type as the one that ruptured in Brumadinho - although 80 structures had their stability certificates renewed.</li><li>Vale says its external auditors refused to sign off on the 13 dams because they adopted more conservative models for their analyses, not because the structures themselves had become more unstable.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447421\" data-linked=\"Vale +4% on higher iron prices despite losing certifications, asset freeze\" data-tweet=\"$VALE $RIO - Vale +4% on higher iron prices despite losing certifications, asset freeze https://seekingalpha.com/news/3447421-valeplus-4-on-higher-iron-prices-despite-losing-certifications-asset-freeze?source=tweet\" data-url=\"https://seekingalpha.com/news/3447421-valeplus-4-on-higher-iron-prices-despite-losing-certifications-asset-freeze\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447420\" data-ts=\"1554144811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSSE\" target=\"_blank\">CSSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447420-chicken-soup-for-soul-pulls-back-after-big-friday\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chicken Soup for the Soul pulls back after big Friday</a></h4><ul>   <li>Chicken Soup for the Soul Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CSSE' title='Chicken Soup for the Soul Entertainment, Inc.'>CSSE</a>) is <font color=\"red\">11.9% lower</font>, giving back some of the gains it made Friday after earnings and a deal with Sony for a stake in Crackle.</li>    <li>Shares rose 36% Friday after <a href=\"https://seekingalpha.com/news/3446722-chicken-soup-soul-jumps-crackle-deal\" target=\"_blank\">news of the deal</a> and the company's <a href=\"https://seekingalpha.com/news/3446815-chickensoup-entertainment-misses-revenue\" target=\"_blank\">earnings</a>, which sported a revenue gain (full year) of more than 150% and EBITDA gains of 180%.</li>    <li>Benchmark responded to the company news by boosting its price target on \"one of the hottest small properties in the media landscape.\" It's set its new target at $18, up from $16 and currently implying 65% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447420\" data-linked=\"Chicken Soup for the Soul pulls back after big Friday\" data-tweet=\"$CSSE - Chicken Soup for the Soul pulls back after big Friday https://seekingalpha.com/news/3447420-chicken-soup-for-soul-pulls-back-after-big-friday?source=tweet\" data-url=\"https://seekingalpha.com/news/3447420-chicken-soup-for-soul-pulls-back-after-big-friday\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447419\" data-ts=\"1554144638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447419-cellcom-israel-leads-technology-gainers-sigma-labs-and-lyft-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellcom Israel leads technology gainers; Sigma Labs and Lyft among losers</a></h4><ul><li><b>Gainers:</b> Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel Ltd.'>CEL</a>) <font color=\"green\">+21%</font>. Atomera (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Incorporated'>ATOM</a>) <font color=\"green\">+18%</font>. Partner Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/PTNR' title='Partner Communications Company Ltd.'>PTNR</a>) <font color=\"green\">+16%</font>. Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc.'>MAXR</a>) <font color=\"green\">+11%</font>. Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers:</b> Creative Realities (NASDAQ:<a href='https://seekingalpha.com/symbol/CREX' title='Creative Realities, Inc.'>CREX</a>) <font color=\"red\">-14%</font>. Sigma Labs (NASDAQ:<a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a>) <font color=\"red\">-11%</font>. Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) <font color=\"red\">-10%</font>. Points International (NASDAQ:<a href='https://seekingalpha.com/symbol/PCOM' title='Points International Ltd.'>PCOM</a>) <font color=\"red\">-10%</font>. O2Micro International (NASDAQ:<a href='https://seekingalpha.com/symbol/OIIM' title='O2Micro International Limited'>OIIM</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447419\" data-linked=\"Cellcom Israel leads technology gainers; Sigma Labs and Lyft among losers\" data-tweet=\"$CEL $ATOM $PTNR - Cellcom Israel leads technology gainers; Sigma Labs and Lyft among losers https://seekingalpha.com/news/3447419-cellcom-israel-leads-technology-gainers-sigma-labs-and-lyft-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447419-cellcom-israel-leads-technology-gainers-sigma-labs-and-lyft-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447418\" data-ts=\"1554144528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEYS\" target=\"_blank\">KEYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447418-keysightplus-2-on-new-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Keysight +2% on new Street-high target</a></h4><ul><li>Stifel maintains a Buy rating on Keysight Technologies (NYSE:<a href='https://seekingalpha.com/symbol/KEYS' title='Keysight Technologies, Inc.'>KEYS</a>) and raises the PT from $87 to the Street-high $100.</li><li>The firm cites long-term growth opportunities after a meeting with company management.</li><li>The \"breadth of opportunities\" are in the \"early stages of multi-year growth.\"</li><li>Stifel says KEYS also has a competitive advantage on 5G and auto tech \"that should drive sustainable market share gains.\"</li><li>KEYS shares are <font color=\"green\">up 2%</font> to $89.08.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447418\" data-linked=\"Keysight +2% on new Street-high target\" data-tweet=\"$KEYS - Keysight +2% on new Street-high target https://seekingalpha.com/news/3447418-keysightplus-2-on-new-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3447418-keysightplus-2-on-new-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447414\" data-ts=\"1554143023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRCM\" target=\"_blank\">CRCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447414-care-comminus-7-on-report-of-scrubbed-listings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Care.com -7% on report of scrubbed listings</a></h4><ul><li>Care.com (NYSE:<a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a>) <font color=\"red\">drops 7%</font> after a <a href=\"https://www.wsj.com/articles/care-com-removes-tens-of-thousands-of-unverified-listings-11554040800?mod=rss_Technology\" target=\"_blank\">WSJ report</a> that the company scrubbed \"tens of thousands of unverified day care center listings\" the day before a <a href=\"https://seekingalpha.com/news/3441504-care-com-minus-13-percent-wsj-report-caregiver-screening\" target=\"_blank\">prior investigation</a> was published.</li><li>A Journal review of the website showed Care.com removed about 72% of its listings. The listings were available as recently as March 1.</li><li>A CRCM spokeswoman confirmed the listings were removed on March 7, which was also when the company reported earnings. The company said 45% of the day-care center listings were removed, and the WSJ's number was higher because it only saw a subset of the total listings.</li><li>The prior WSJ report found a number of problems with the center listings including incorrect licensing information and limited vetting on Care.com's part.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447414\" data-linked=\"Care.com -7% on report of scrubbed listings\" data-tweet=\"$CRCM - Care.com -7% on report of scrubbed listings https://seekingalpha.com/news/3447414-care-comminus-7-on-report-of-scrubbed-listings?source=tweet\" data-url=\"https://seekingalpha.com/news/3447414-care-comminus-7-on-report-of-scrubbed-listings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447413\" data-ts=\"1554142966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447413-new-52-week-high-for-chipotle-on-loyalty-program-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New 52-week high for Chipotle on loyalty program buzz</a></h4><ul> <li>Barclays says Chipotle (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='red'>-0.7%</font>) has seen increased <a href=\"https://www.cnbc.com/2019/04/01/chipotles-loyalty-program-is-driving-app-downloads-barclays-says.html\" target=\"_blank\">visits</a> from active users of the restaurant company's app after the launch of the loyalty program.</li> <li>Still, the firm isn't getting ahead of itself based on the early report. \"We remain prudently cautious until we see stabilization in digital metric trends,\" notes analyst Jeffrey Bernstein.</li> <li>Chipotle traded at a new 52-week high of $715.57 earlier in today's session as buzz over the loyalty program remains strong.</li> <li>Chipotle is due to report earnings on April 24, at which time management may update on the impact of the loyalty program.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447413\" data-linked=\"New 52-week high for Chipotle on loyalty program buzz\" data-tweet=\"$CMG - New 52-week high for Chipotle on loyalty program buzz https://seekingalpha.com/news/3447413-new-52-week-high-for-chipotle-on-loyalty-program-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3447413-new-52-week-high-for-chipotle-on-loyalty-program-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447410\" data-ts=\"1554142408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYFT\" target=\"_blank\">LYFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447410-lyft-sinks-10-hedgeye-sees-big-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lyft sinks 10%; Hedgeye sees big downside</a></h4><ul><li>Market share gains for Lyft (<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a> <font color='red'>-10.3%</font>) are set to stabilize, not accelerate, <a href=\"https://twitter.com/KeithMcCullough/status/1112716824204984322\" target=\"_blank\">says analyst Ami Joseph</a>. This makes valuation an issue, and Lyft deserves something less than Uber's (<a href='https://seekingalpha.com/symbol/UBER' title='Uber'>UBER</a>) 2x enterprise value/gross bookings.</li><li>Lyft at these prices is an \"iffy investment,\" says Joseph, who sees <font color=\"red\">25% downside</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447410\" data-linked=\"Lyft sinks 10%; Hedgeye sees big downside\" data-tweet=\"$LYFT $LYFT $UBER - Lyft sinks 10%; Hedgeye sees big downside https://seekingalpha.com/news/3447410-lyft-sinks-10-hedgeye-sees-big-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3447410-lyft-sinks-10-hedgeye-sees-big-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447409\" data-ts=\"1554142223\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COP\" target=\"_blank\">COP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447409-conoco-in-talks-chrysaor-over-north-sea-fields-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conoco in talks with Chrysaor over North Sea fields - Bloomberg</a></h4><ul><li>ConocoPhillips (<a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color=\"green\">+1.5%</font>) is <a href=\"https://finance.yahoo.com/news/conoco-said-hold-talks-chrysaor-162632049.html\" target=\"_blank\">in talks to sell a package of North Sea assets</a> to Chrysaor Holdings after earlier discussions with U.K. billionaire Jim Ratcliffe collapsed, Bloomberg reports.</li><li>Chrysaor is the front-runner for a deal which could be announced in the coming weeks, after COP opened up the bidding in January after efforts to sell the assets to Ratcliffe\u2019s Ineos for as much as $3B failed, according to the report.</li><li>If Chrysaor could complete a deal for the COP assets, it would increase its overall production by ~60K bbl/day from 125K bbl/day currently.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447409\" data-linked=\"Conoco in talks with Chrysaor over North Sea fields - Bloomberg\" data-tweet=\"$COP - Conoco in talks with Chrysaor over North Sea fields - Bloomberg https://seekingalpha.com/news/3447409-conoco-in-talks-chrysaor-over-north-sea-fields-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3447409-conoco-in-talks-chrysaor-over-north-sea-fields-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447407\" data-ts=\"1554142157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUTL\" target=\"_blank\">AUTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447407-autolus-down-1-on-auto1-data-in-adults-all\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autolus down 1% on AUTO1 data in adults with ALL</a></h4><ul><li>Thinly traded Autolus Therapeutics (<a href='https://seekingalpha.com/symbol/AUTL' title='Autolus Therapeutics plc'>AUTL</a> <font color=\"red\">-1.2%</font>) slips on below-average volume on the heels of <a href=\"https://seekingalpha.com/pr/17461763-initial-results-autolus-therapeutics-allcar19-phase-1-2-trial-adult-acute-lymphoblastic\" target=\"_blank\">initial data</a> from from the adult cohort in a Phase 1/2 clinical trial, ALLCAR19, evaluating its AUTO1 CAR-T candidate in patients with acute lymphoblastic leukemia &#40;ALL&#41;. The results were presented at AACR in Atlanta.</li><li>88.9% (n=8/9) of evaluable patients experienced molecular complete responses (no evidence of cancer via CT or PET imaging).</li><li>On the safety front, no patients were admitted to the ICU due to cytokine release syndrome &#40;CRS&#41;. One patient developed serious neurotoxicity following high levels of CAR T expression that was quickly reversed with steroids. Four participants died while on study, two from leukemia progression and two from sepsis.</li><li>The company <a href=\"https://seekingalpha.com/news/3434466-autolus-slips-1-percent-auto1-data\" target=\"_blank\">reported </a>pediatric data in February.</li><li>Management will host a conference call tomorrow, April 2, at 8:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447407\" data-linked=\"Autolus down 1% on AUTO1 data in adults with ALL\" data-tweet=\"$AUTL - Autolus down 1% on AUTO1 data in adults with ALL https://seekingalpha.com/news/3447407-autolus-down-1-on-auto1-data-in-adults-all?source=tweet\" data-url=\"https://seekingalpha.com/news/3447407-autolus-down-1-on-auto1-data-in-adults-all\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447401\" data-ts=\"1554141611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447401-ion-geophysical-and-lithium-americas-among-energy-materials-gainers-alexco-resource-and-new\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ION Geophysical and Lithium Americas among Energy/Materials gainers; Alexco Resource and New Concept Energy among losers</a></h4><ul><li><b>Gainers: </b>ION Geophysical (NYSE:<a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a>) <font color=\"green\">+15%</font>. Lithium Americas (NYSE:<a href='https://seekingalpha.com/symbol/LAC' title='Lithium Americas Corp.'>LAC</a>) <font color=\"green\">+12%</font>. Mexco Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a>) <font color=\"green\">+9%</font>. Nabors Industries (NYSE:<a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a>) <font color=\"green\">+9%</font>. Aluminum Corporation of China (NYSE:<a href='https://seekingalpha.com/symbol/ACH' title='Aluminum Corporation of China Limited'>ACH</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Alexco Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corp.'>AXU</a>) <font color=\"red\">-10%</font>. New Concept Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>) <font color=\"red\">-9%</font>. Seabridge Gold (NYSE:<a href='https://seekingalpha.com/symbol/SA' title='Seabridge Gold Inc.'>SA</a>) <font color=\"red\">-8%</font>. Barnwell Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/BRN' title='Barnwell Industries, Inc.'>BRN</a>) <font color=\"red\">-8%</font>. PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447401\" data-linked=\"ION Geophysical and Lithium Americas among Energy/Materials gainers; Alexco Resource and New Concept Energy among losers\" data-tweet=\"$IO $LAC $MXC - ION Geophysical and Lithium Americas among Energy/Materials gainers; Alexco Resource and New Concept Energy among losers https://seekingalpha.com/news/3447401-ion-geophysical-and-lithium-americas-among-energy-materials-gainers-alexco-resource-and-new?source=tweet\" data-url=\"https://seekingalpha.com/news/3447401-ion-geophysical-and-lithium-americas-among-energy-materials-gainers-alexco-resource-and-new\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447394\" data-ts=\"1554140851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNST\" target=\"_blank\">CNST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447394-constellation-pharma-down-1-on-cpiminus-1205-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Constellation Pharma down 1% on CPI-1205 data</a></h4><ul><li>Thinly traded micro cap Constellation Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CNST' title='Constellation Pharmaceuticals, Inc.'>CNST</a> <font color=\"red\">-1.4%</font>) slips on average volume in response to <a href=\"https://seekingalpha.com/pr/17461754-constellation-pharmaceuticals-presents-results-phase-1b-portion-prostar-clinical-trial\" target=\"_blank\">results</a> from the Phase 1b portion of a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03480646?lead=constellation+pharmaceuticals&amp;rank=2\" target=\"_blank\">ProSTAR</a>, evaluating CPI-1205, combined with Pfizer and Astellas' Xtandi (enzalutamide) or J &amp; J's Zytiga (abiraterone)/prednisone, in patients with metastatic castration-resistant prostate cancer. The data are being presented at AACR in Atlanta.</li><li>Clinical activity was observed in both arms, including at least a 50% drop in PSA levels. Specifically, 20% (n=2/10) patients in the CPI-1205 + abiraterone arm who were negative for a genetic variant called AR-V7 experienced at least an 80% reduction in PSA while 27% (n=3/11) in the CPI-1205 group (negative for AR-V7) did.</li><li>The disease control rates (responders + stable cancer) in both groups were 50% (n=4/8) and 60% (n=3/5), respectively.</li><li>The Phase 2 portion was launched in Q4 2018. Preliminary data should be available in H2.</li><li>CPI-1205 inhibits an enzyme called enhancer of zeste homolog 2 (EZH2), associated with many types of cancer when overexpressed.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"red\">-0.6%</font>), (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color=\"green\">+0.8%</font>), (<a href='https://seekingalpha.com/symbol/ALPMY' title='Astellas Pharma Inc.'>OTCPK:ALPMY</a> <font color=\"green\">+1.7%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447394\" data-linked=\"Constellation Pharma down 1% on CPI-1205 data\" data-tweet=\"$CNST $JNJ $PFE - Constellation Pharma down 1% on CPI-1205 data https://seekingalpha.com/news/3447394-constellation-pharma-down-1-on-cpiminus-1205-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447394-constellation-pharma-down-1-on-cpiminus-1205-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447383\" data-ts=\"1554138422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447383-wheeler-real-estate-investment-trust-leads-financial-gainers-china-rapid-finance-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wheeler Real Estate Investment Trust leads financial gainers; China Rapid Finance among losers</a></h4><ul><li><b>Gainers:</b> Wheeler Real Estate Investment Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust, Inc.'>WHLR</a>) <font color=\"green\">+9%</font>. Oxbridge Re Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a>) <font color=\"green\">+8%</font>. Noah Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"green\">+8%</font>. LexinFintech Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd.'>LX</a>) <font color=\"green\">+7%</font>. U.S. Global Investors (NASDAQ:<a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Crawford &amp; Company (CRD-B) <font color=\"red\">-11%</font>. Crawford &amp; Company (CRD-A) <font color=\"red\">-7%</font>. China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance Limited'>XRF</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447383\" data-linked=\"Wheeler Real Estate Investment Trust leads financial gainers; China Rapid Finance among losers\" data-tweet=\"$WHLR $OXBR $NOAH - Wheeler Real Estate Investment Trust leads financial gainers; China Rapid Finance among losers https://seekingalpha.com/news/3447383-wheeler-real-estate-investment-trust-leads-financial-gainers-china-rapid-finance-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447383-wheeler-real-estate-investment-trust-leads-financial-gainers-china-rapid-finance-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447381\" data-ts=\"1554138313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447381-catalyst-bios-marzeptacog-alfa-orphan-drug-in-europe-for-hemophilia-b-shares-up-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio&#39;s marzeptacog alfa an Orphan Drug in Europe for hemophilia B; shares up 11%</a></h4><ul><li>The European Commission has <a href=\"https://seekingalpha.com/pr/17461731-catalyst-biosciences-receives-orphan-designation-european-commission-marzeptacog-alfa\" target=\"_blank\">designated </a>Catalyst Biosciences' (<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color=\"green\">+10.6%</font>) Factor VIIa variant marzeptacog alfa an Orphan Drug for the treatment of hemophilia B with or without inhibitors.</li><li>Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.</li><li>Topline data on nine patients in a Phase 2/3 study should be available in Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447381\" data-linked=\"Catalyst Bio&#39;s marzeptacog alfa an Orphan Drug in Europe for hemophilia B; shares up 11%\" data-tweet=\"$CBIO - Catalyst Bio&#39;s marzeptacog alfa an Orphan Drug in Europe for hemophilia B; shares up 11% https://seekingalpha.com/news/3447381-catalyst-bios-marzeptacog-alfa-orphan-drug-in-europe-for-hemophilia-b-shares-up-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3447381-catalyst-bios-marzeptacog-alfa-orphan-drug-in-europe-for-hemophilia-b-shares-up-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447379\" data-ts=\"1554138016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447379-hovnanian-enterprises-leads-industrial-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hovnanian Enterprises leads industrial gainers</a></h4><ul><li><b>Gainers: </b>Hovnanian Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>) <font color=\"green\">+12%</font>. Comstock Holding Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/CHCI' title='Comstock Holding Companies, Inc.'>CHCI</a>) <font color=\"green\">+9%</font>. Gates Industrial (NYSE:<a href='https://seekingalpha.com/symbol/GTES' title='Gates Industrial Corporation plc'>GTES</a>) <font color=\"green\">+8%</font>. Coda Octopus Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CODA' title='Coda Octopus Group, Inc.'>CODA</a>) <font color=\"green\">+8%</font>. The New Home Company (NYSE:<a href='https://seekingalpha.com/symbol/NWHM' title='The New Home Company Inc.'>NWHM</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>None</li></ul><div class=\"tiny-share-widget\" data-id=\"3447379\" data-linked=\"Hovnanian Enterprises leads industrial gainers\" data-tweet=\"$HOV $CHCI $GTES - Hovnanian Enterprises leads industrial gainers https://seekingalpha.com/news/3447379-hovnanian-enterprises-leads-industrial-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447379-hovnanian-enterprises-leads-industrial-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447377\" data-ts=\"1554137914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LAC\" target=\"_blank\">LAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447377-lithium-americas-gets-160m-investment-for-cauchari-olaroz-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lithium Americas gets $160M investment for Cauchari-Olaroz project</a></h4><ul><li>Lithium Americas (<a href='https://seekingalpha.com/symbol/LAC' title='Lithium Americas Corp.'>LAC</a> <font color=\"green\">+11.2%</font>) surges on news that China's Ganfeng Lithium <a href=\"https://seekingalpha.com/pr/17460892-lithium-americas-reports-2018-financial-operating-results\" target=\"_blank\">will invest $160M</a> in LAC's Cauchari-Olaroz lithium  brine project in Argentina, raising its stake to 50% from 37.5% previously.</li><li>The cash infusion brings LAC closer to its goal of becoming Argentina's largest lithium producer, ahead of Orocobre (<a href='https://seekingalpha.com/symbol/OROCF' title='Orocobre Limited'>OTCPK:OROCF</a>) and Livent (NYSE:<a href='https://seekingalpha.com/symbol/LTHM' title='Livent Corporation'>LTHM</a>), the country's two top producers.</li><li>LAC says construction remains on track for first production at Cauchari-Olaroz in H2 2020, and updates its measured and Indicated mineral resource at the project  to 17.9M metric tons of of lithium carbonate equivalent.</li><li>LAC also reports an adjusted Q4 loss of $9.6M, or $0.05/share, on revenue of $1.5M, while its full-year loss narrowed to $28.3M, or $0.32/share, on revenue of $4.8M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447377\" data-linked=\"Lithium Americas gets $160M investment for Cauchari-Olaroz project\" data-tweet=\"$LAC $OROCF $LTHM - Lithium Americas gets $160M investment for Cauchari-Olaroz project https://seekingalpha.com/news/3447377-lithium-americas-gets-160m-investment-for-cauchari-olaroz-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3447377-lithium-americas-gets-160m-investment-for-cauchari-olaroz-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447373\" data-ts=\"1554137395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447373-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong>Pulmatrix (NASDAQ:<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a>) <font color=\"green\">+120%</font>. CM Seven Star Acquisition (NASDAQ:<a href='https://seekingalpha.com/symbol/CMSS' title='CM Seven Star Acquisition Corporation'>CMSS</a>) <font color=\"green\">+42%</font>. PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+21%</font>. Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel Ltd.'>CEL</a>) <font color=\"green\">+20%</font>. Partner Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/PTNR' title='Partner Communications Company Ltd.'>PTNR</a>) <font color=\"green\">+16%</font>. Translate Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/TBIO' title='Translate Bio, Inc.'>TBIO</a>) <font color=\"green\">+16%</font>. Atomera (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Incorporated'>ATOM</a>) <font color=\"green\">+16%</font>.IMAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/IMAC' title='IMAC Holdings, Inc.'>IMAC</a>) <font color=\"green\">+14%</font>. Maxar Technologies (NYSE:<a href='https://seekingalpha.com/symbol/MAXR' title='Maxar Technologies Inc.'>MAXR</a>) <font color=\"green\">+13%</font>. TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) <font color=\"green\">+13%</font>.</li><li><strong>Losers: </strong>comScore (NASDAQ:<a href='https://seekingalpha.com/symbol/SCOR' title='comScore, Inc.'>SCOR</a>) <font color=\"red\">-24%</font>. Creative Realities (NASDAQ:<a href='https://seekingalpha.com/symbol/CREX' title='Creative Realities, Inc.'>CREX</a>) <font color=\"red\">-18%</font>. Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi, Inc.'>FAMI</a>) <font color=\"red\">-20%</font>. Barnwell Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/BRN' title='Barnwell Industries, Inc.'>BRN</a>) <font color=\"red\">-13%. </font>Chicken Soup for the Soul Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CSSE' title='Chicken Soup for the Soul Entertainment, Inc.'>CSSE</a>) <font color=\"red\">-12%</font>. Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"red\">-11%</font>. Sears Hometown and Outlet Stores (NASDAQ:<a href='https://seekingalpha.com/symbol/SHOS' title='Sears Hometown and Outlet Stores, Inc.'>SHOS</a>) <font color=\"red\">-11%</font>. Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) <font color=\"red\">-11%</font>. New Concept Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>) <font color=\"red\">-9%</font>. NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447373\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$PULM $KXIN $PHAS - Midday Gainers / Losers https://seekingalpha.com/news/3447373-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447373-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447371\" data-ts=\"1554136613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHAS\" target=\"_blank\">PHAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447371-phasebio-continues-pb2452-stoked-up-move-shares-ahead-22\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PhaseBio continues PB2452-stoked up move, shares ahead 22%</a></h4><ul><li>Thinly traded micro cap PhaseBio Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a> <font color=\"green\">+22.3%</font>) is up on almost a 5x surge in volume. Shares have tripled since March 18 when it <a href=\"https://seekingalpha.com/news/3443559-phasebio-102-percent-premarket-positive-pb2452-data\" target=\"_blank\">announced </a>positive early-stage data on PB2452, a reversal agent for AstraZeneca's anticoagulant Brilinta (ticagrelor).</li><li>On the working capital front, at the end of 2018 it had $61.0M in cash and equivalents. Operations consumed $17.1M during the year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447371\" data-linked=\"PhaseBio continues PB2452-stoked up move, shares ahead 22%\" data-tweet=\"$PHAS - PhaseBio continues PB2452-stoked up move, shares ahead 22% https://seekingalpha.com/news/3447371-phasebio-continues-pb2452-stoked-up-move-shares-ahead-22?source=tweet\" data-url=\"https://seekingalpha.com/news/3447371-phasebio-continues-pb2452-stoked-up-move-shares-ahead-22\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447365\" data-ts=\"1554136032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIBT\" target=\"_blank\">RIBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447365-ricebran-technologies-down-6-post-fy18-results-lowers-fy19-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RiceBran Technologies down 6% post FY18 results; lowers FY19 revenue guidance</a></h4><ul><li>RiceBran Technologies (<a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a> <font color=\"red\">-6.5%</font>) reported revenues growth of 10.5% Y/Y to $14.76M for FY18, inclusive of $0.9M in revenue from Golden Ridge Rice Mills.</li><li>FY Gross margin <font color=\"red\">declined by 819 bps </font>to 20.2%.</li><li>Loss from operations expanded to $8.2M, compared to $6.1M last year.</li><li>SG&amp;A expenses were $11.19M (+13.2% Y/Y) and as percentage of revenue 75.8% up by 180 bps.</li><li>Adj. EBITDA was negative $6.4M, compared to negative $4.1M a year ago.</li><li>Company has cash and equivalents of $7M, as of December 31, 2018.</li><li>Company announces the acquisition of MGI Grain in East Grand Forks, MN for $3.5M. MGI Grain is an ingredient company focused on barley and oat products. MGI Grain presently has annually sales near $3M and has positive adjusted EBITDA</li><li><strong>FY19 Guidance: </strong>Revenues of ~$37M to $40M (prior +$40M); and expects to attain positive Adj. EBITDA.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447138-ricebran-technologies-reports-fy-results\" target=\"_blank\">RiceBran Technologies reports FY results</a> (April 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447365\" data-linked=\"RiceBran Technologies down 6% post FY18 results; lowers FY19 revenue guidance\" data-tweet=\"$RIBT - RiceBran Technologies down 6% post FY18 results; lowers FY19 revenue guidance https://seekingalpha.com/news/3447365-ricebran-technologies-down-6-post-fy18-results-lowers-fy19-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3447365-ricebran-technologies-down-6-post-fy18-results-lowers-fy19-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447364\" data-ts=\"1554135751\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCORF\" target=\"_blank\">CCORF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447364-canaccordplus-4_1-pares-back-u-k-capital-markets-activity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canaccord +4.1% as it pares back U.K. capital markets activity</a></h4><ul><li>Canaccord Genuity (<a href='https://seekingalpha.com/symbol/CCORF' title='Canaccord Genuity Group Inc.'>OTCPK:CCORF</a> <font color='green'>+4.1%</font>)<font color=\"green\"> rises 4.1%</font> the day after it announces plans<a href=\"https://seekingalpha.com/pr/17460517-canaccord-genuity-group-inc-announces-restructuring-uk-capital-markets-business\" target=\"_blank\"> to cut back</a> on its U.K.-based capital markets activities in response to the prolonged uncertainty arising from Brexit.</li><li>Sees \"significant reduction\" in its London-based capital markets staff level.</li><li>Expects to record a C$12M charge in fiscal Q4 ended March 31, 2019.</li><li>Restructuring doesn't affect Canaccord's wealth management operations in the U.K. and Europe, nor does it affect any other businesses in the Canaccord Genuity Group.</li><li>\"The plan we have announced today will allow us to redeploy excess capital from our UK capital markets business, reduce our exposure to the volatility and historical losses that we have experienced with capital raising, advisory and trading activities in the region, and align our UK capital markets business with our broader global capabilities,\" says Canaccord President and CEO Dan Daviau.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447364\" data-linked=\"Canaccord +4.1% as it pares back U.K. capital markets activity\" data-tweet=\"$CCORF - Canaccord +4.1% as it pares back U.K. capital markets activity https://seekingalpha.com/news/3447364-canaccordplus-4_1-pares-back-u-k-capital-markets-activity?source=tweet\" data-url=\"https://seekingalpha.com/news/3447364-canaccordplus-4_1-pares-back-u-k-capital-markets-activity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447357\" data-ts=\"1554134401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447357-tata-motors-and-adient-among-consumer-gainers-iconix-brand-group-and-ricebran-technologies-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tata Motors and Adient among consumer gainers; Iconix Brand Group and RiceBran Technologies in losers</a></h4><ul><li><b>Gainers: </b>Adient (NYSE:<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a>) <font color=\"green\">+12%</font>. SORL Auto Parts (NASDAQ:<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>) <font color=\"green\">+10%</font>. Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+9%</font>. Tata Motors (NYSE:<a href='https://seekingalpha.com/symbol/TTM' title='Tata Motors Limited'>TTM</a>) <font color=\"green\">+9%</font>. Delphi Technologies (NYSE:<a href='https://seekingalpha.com/symbol/DLPH' title='Delphi Technologies PLC'>DLPH</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"red\">-10%</font>. RiceBran Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447357\" data-linked=\"Tata Motors and Adient among consumer gainers; Iconix Brand Group and RiceBran Technologies in losers\" data-tweet=\"$ADNT $SORL $VFF - Tata Motors and Adient among consumer gainers; Iconix Brand Group and RiceBran Technologies in losers https://seekingalpha.com/news/3447357-tata-motors-and-adient-among-consumer-gainers-iconix-brand-group-and-ricebran-technologies-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3447357-tata-motors-and-adient-among-consumer-gainers-iconix-brand-group-and-ricebran-technologies-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447352\" data-ts=\"1554133589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447352-intel-lays-off-hundreds-of-workers-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel lays off hundreds of IT workers - report</a></h4><ul><li>Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) has <a href=\"https://www.oregonlive.com/silicon-forest/2019/03/intel-lays-off-hundreds-of-tech-administrators.html\" target=\"_blank\">laid off</a> a \"substantial number\" of IT workers at sites across the company in the past week, according to a report from The Oregonian on Friday.</li><li>Sources say the layoffs numbered in the hundreds. Intel confirmed the job cuts but didn't confirm the number or provide a reason.</li><li>Intel shares are <font color=\"green\">up 1.3%</font> to $54.38.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447352\" data-linked=\"Intel lays off hundreds of IT workers - report\" data-tweet=\"$INTC - Intel lays off hundreds of IT workers - report https://seekingalpha.com/news/3447352-intel-lays-off-hundreds-of-workers-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3447352-intel-lays-off-hundreds-of-workers-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447351\" data-ts=\"1554133579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCOR\" target=\"_blank\">SCOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447351-comscoreminus-22-to-near-three-month-low-bulls-cut-ratings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ComScore -22% to near three-month low; bulls cut ratings</a></h4><ul>   <li>ComScore (NASDAQ:<a href='https://seekingalpha.com/symbol/SCOR' title='comScore, Inc.'>SCOR</a>) is sliding further in the wake of its <a href=\"https://seekingalpha.com/news/3447253-comscore-minus-13_1-percent-departures-ceo-president\" target=\"_blank\">executive exits</a>, now <font color=\"red\">down 22%</font> to its lowest point since Jan. 4.</li>    <li>A few sell-side bulls have headed to the sidelines in response, citing the uncertainty coming from the company's losing its CEO and president. Oppenheimer has cut to Market Perform from Outperform.</li>    <li>SunTrust Robinson Humphrey has also gone to Hold from Buy, and cut its price target to $21 from $27. Shares are at $15.79 now.</li>    <li>And Loop Capital has cut to Hold from Buy as well, and trimmed its price target to $22 from $32.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447351\" data-linked=\"ComScore -22% to near three-month low; bulls cut ratings\" data-tweet=\"$SCOR - ComScore -22% to near three-month low; bulls cut ratings https://seekingalpha.com/news/3447351-comscoreminus-22-to-near-three-month-low-bulls-cut-ratings?source=tweet\" data-url=\"https://seekingalpha.com/news/3447351-comscoreminus-22-to-near-three-month-low-bulls-cut-ratings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447344\" data-ts=\"1554132843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNDX\" target=\"_blank\">SNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447344-syndax-down-4-on-updated-entinostat-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syndax down 4% on updated entinostat data</a></h4><ul><li>Thinly traded micro cap Syndax Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color=\"red\">-4.4%</font>) slips on below-average volume on the heels of <a href=\"https://seekingalpha.com/pr/17461560-syndax-pharmaceuticals-presents-updated-phase-2-data-encore-601-trial-entinostat-combination\" target=\"_blank\">updated results</a> from a Phase 1b/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02909452?lead=syndax&amp;phase=0&amp;rank=7\" target=\"_blank\">ENCORE 601</a>, evaluating HDAC inhibitor entinostat plus Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=\"green\">+0.1%</font>) Keytruda (pembrolizumab) in patients with solid tumors. The data were presented at AACR in Atlanta.</li><li>In the melanoma arm, 53 treated patients who had progressed after anti-PD-1 therapy, showed a 19% (n=10/53) response rate, including one complete responder. The clinical benefit rate (responders + stable cancer) was 36% (n=19/53) in those patients with stable disease greater than six months. Median duration of response was 13 months (range of 3 - 20 months).</li><li>In the non-small cell lung cancer &#40;NSCLC&#41; arm, the results were less definitive. Updated data \"continue to support the association of high baseline classical monocytes (type of white blood cell) with improved clinical outcome.\" Median duration of response was 8 months (range of 3 - 18 months).</li><li>In September 2018, the company <a href=\"https://seekingalpha.com/news/3392579-syndax-pharma-12-percent-hours-updated-mid-stage-data-entinostat-pembrolizumab-combo-lung\" target=\"_blank\">reported </a>a 10% response rate in the lung cancer arm with a median duration of 5.3 months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447344\" data-linked=\"Syndax down 4% on updated entinostat data\" data-tweet=\"$SNDX $MRK - Syndax down 4% on updated entinostat data https://seekingalpha.com/news/3447344-syndax-down-4-on-updated-entinostat-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447344-syndax-down-4-on-updated-entinostat-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447341\" data-ts=\"1554132240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447341-analysts-ding-l-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts ding L Brands</a></h4><ul> <li>L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='red'>-0.8%</font>) is the target of negative comments from two investment firms today.</li><li>The highly-anticipated <a href=\"https://www.barrons.com/articles/victorias-secret-l-brands-stock-analyst-calls-51554131187\" target=\"_blank\">return</a> of Victoria's Secret swimsuit line could be a dud, according to MKM Partners analyst Roxanne Meyer.</li> <li>Meyer says the collection of swimwear, cover-ups, sunglasses and accessories isn't in line with Victoria's Secret's strength. She asks if it makes sense that swimsuits are only available online?\"</li> <li>Meanwhile, Jefferies sees the Pink business as the biggest problem for L Brands. \"We see sales at PINK cut in half or more which will create massive operating deleverage in the earnings model,\" warns analyst Randal Konik.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447341\" data-linked=\"Analysts ding L Brands\" data-tweet=\"$LB - Analysts ding L Brands https://seekingalpha.com/news/3447341-analysts-ding-l-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3447341-analysts-ding-l-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447340\" data-ts=\"1554132113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNRR\" target=\"_blank\">VNRR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447340-vanguard-files-for-chapter-11-bankruptcy-second-time-in-two-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vanguard files for Chapter 11 bankruptcy; second time in two years</a></h4><ul><li>Vanguard Natural Resources (<a href='https://seekingalpha.com/symbol/VNRR' title='Vanguard Natural Resources, Inc.'>OTCQX:VNRR</a> <font color='red'>-72%</font>) <a href=\"https://seekingalpha.com/pr/17460791-vanguard-natural-resources-inc-files-chapter-11-protection\" target=\"_blank\">files for Chapter 11 bankruptcy</a> protection, its second bankruptcy in less than two years.</li><li>VNRR says Citibank has agreed to make available $65M in debtor-in-possession financing.</li><li>VNRR had $8.6M in free cash and <a href=\"https://www.wsj.com/articles/oil-and-gas-company-vanguard-returns-to-bankruptcy-11554128629\" target=\"_blank\">no agreement with lenders</a> about how to restructure $882M in debt, <em>WSJ</em> reports, citing filings with the U.S. Bankruptcy Court in Houston.</li><li>Talks are underway with Citi and other lenders but holders of only ~40% of the company\u2019s debt are involved in restructuring negotiations, WSJ reports; it will take an agreement from holders of at least two-thirds of the debt to get VNRR safely through Chapter 11.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447340\" data-linked=\"Vanguard files for Chapter 11 bankruptcy; second time in two years\" data-tweet=\"$VNRR $VNRRQ - Vanguard files for Chapter 11 bankruptcy; second time in two years https://seekingalpha.com/news/3447340-vanguard-files-for-chapter-11-bankruptcy-second-time-in-two-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3447340-vanguard-files-for-chapter-11-bankruptcy-second-time-in-two-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447338\" data-ts=\"1554131920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447338-publicis-groupeminus-4-confirms-consideration-of-epsilon-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Publicis Groupe -4% as it confirms consideration of Epsilon bid</a></h4><ul>   <li>Publicis Groupe (<a href='https://seekingalpha.com/symbol/PUBGY' title='Publicis Groupe S.A.'>OTCQX:PUBGY</a>) is <font color=\"red\">off 4%</font> in U.S. trading after it confirmed it was studying the purchase of Alliance Data Systems' (<a href=\"http://seekingalpha.com/symbol/ADS\" target=\"_blank\">ADS</a> <font color=\"green\">+0.4%</font>) Epsilon, in what would be its biggest deal ever.</li>    <li>That's a unit that could bring $5B in the sale process launched by Alliance -- a value about a third of the enterprise value of Publicis in total.</li>    <li>A joint bid from Goldman-Advent is also reportedly in the works for Epsilon.</li>    <li>Epsilon is a major player in data and targeted marketing solutions.</li>    <li>Publicis prevailing in the bid would be challenging and viewed \"cautiously\" by the market, BofA Merrill Lynch says of the potential deal, which it calls \"meaningful and risky.\" Epsilon has been ex-growth since 2015 with declining profitability. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447338\" data-linked=\"Publicis Groupe -4% as it confirms consideration of Epsilon bid\" data-tweet=\"$PUBGY $ADS - Publicis Groupe -4% as it confirms consideration of Epsilon bid https://seekingalpha.com/news/3447338-publicis-groupeminus-4-confirms-consideration-of-epsilon-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3447338-publicis-groupeminus-4-confirms-consideration-of-epsilon-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447334\" data-ts=\"1554131382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447334-renault-discloses-suspicious-payments-tied-to-ghosn\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Renault discloses suspicious payments tied to Ghosn</a></h4><ul> <li>Renault (<a href='https://seekingalpha.com/symbol/RNSDF' title='Renault SA'>OTC:RNSDF</a>, <a href='https://seekingalpha.com/symbol/RNLSY' title='Renault SA'>OTCPK:RNLSY</a>) has <a href=\"https://www.reuters.com/article/us-nissan-ghosn-renault-oman-exclusive/exclusive-renault-alerts-prosecutors-over-oman-dealer-payments-under-ghosn-idUSKCN1RD2KV\" target=\"_blank\">disclosed</a> to French prosecutors suspicious payments in double-digit millions to a Renault-Nissan business partner in Oman during the tenure of CEO Carlos Ghosn,according to a Reuters exclusive. The evidence suggests the funds ended up at a Lebanese company controlled by Ghosn associates.</li> <li>Sources indicate the determination was made as part of an internal investigation at the French automaker.</li> <li>Shares of Renault are <font color=\"green\">up 3.1%</font> in Paris.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447334\" data-linked=\"Renault discloses suspicious payments tied to Ghosn\" data-tweet=\"$RNSDF $RNLSY - Renault discloses suspicious payments tied to Ghosn https://seekingalpha.com/news/3447334-renault-discloses-suspicious-payments-tied-to-ghosn?source=tweet\" data-url=\"https://seekingalpha.com/news/3447334-renault-discloses-suspicious-payments-tied-to-ghosn\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447323\" data-ts=\"1554131233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYCC\" target=\"_blank\">CYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447323-cyclacel-down-4-on-sapacitabine-seliciclib-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cyclacel down 4% on sapacitabine/seliciclib data</a></h4><ul><li>Nano cap Cyclacel Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color=\"red\">-3.9%</font>) slips on average volume in response to <a href=\"https://seekingalpha.com/pr/17460797-cyclacel-announces-presentation-phase-1-data-sapacitabine-regimen-patients-brca-mutant-breast\" target=\"_blank\">results </a>from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT00999401?lead=cyclacel&amp;phase=0&amp;rank=4\" target=\"_blank\">Phase 1 clinical trial</a> evaluating a sequential regimen of sapacitabine and seliciclib in patients with BRCA-positive metastatic breast cancer. The data, apparently underwhelming to investors, were presented at AACR in Atlanta.</li><li>The results showed that the regimen was safe with a clinical benefit rate &#40;CBR&#41; (responders + stable cancer) of 30%. Specifically, out of 20 subjects, two experienced partial responses and four experienced stable cancer for at least six months.</li><li>Ignoring specific durations, the CBR was 60% (n=12/20), but the number of partial responders remained two.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447323\" data-linked=\"Cyclacel down 4% on sapacitabine/seliciclib data\" data-tweet=\"$CYCC - Cyclacel down 4% on sapacitabine/seliciclib data https://seekingalpha.com/news/3447323-cyclacel-down-4-on-sapacitabine-seliciclib-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447323-cyclacel-down-4-on-sapacitabine-seliciclib-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447332\" data-ts=\"1554131072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447332-cel-sci-and-advaxis-among-healthcare-gainers-puma-biotechnology-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CEL-SCI and Advaxis among healthcare gainers; Puma Biotechnology leads the losers</a></h4><ul><li><b>Gainers: </b>Pulmatrix (NASDAQ:<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a>) <font color=\"green\">+115%</font>. Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"green\">+25%</font>. CEL-SCI (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVM' title='CEL-SCI Corporation'>CVM</a>) <font color=\"green\">+22%</font>. PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+21%</font>. TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) <font color=\"green\">+12%</font>.</li><li><b>Losers: </b>Puma Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) <font color=\"red\">-9%</font>. Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics, Inc.'>SEEL</a>) <font color=\"red\">-8%</font>. Inspire Medical Systems (NYSE:<a href='https://seekingalpha.com/symbol/INSP' title='Inspire Medical Systems, Inc.'>INSP</a>) <font color=\"red\">-7%</font>. Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"red\">-7%</font>. NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447332\" data-linked=\"CEL-SCI and Advaxis among healthcare gainers; Puma Biotechnology leads the losers\" data-tweet=\"$PULM $ADXS $CVM - CEL-SCI and Advaxis among healthcare gainers; Puma Biotechnology leads the losers https://seekingalpha.com/news/3447332-cel-sci-and-advaxis-among-healthcare-gainers-puma-biotechnology-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447332-cel-sci-and-advaxis-among-healthcare-gainers-puma-biotechnology-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447329\" data-ts=\"1554130890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447329-3d-systemsplus-1-on-nokia-integration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D Systems +1% on Nokia integration</a></h4><ul><li>3D Systems (NYSE:<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corporation'>DDD</a>) announces that Nokia, rms Company, and GF Precicast have integrated its additive manufacturing solutions to their production workflows.</li><li>Nokia added 3D Systems' Figure 4 Standalone to its \"Factory in a Box\" mobile manufacturing solution.</li><li>3D shares are <font color=\"green\">up 1%</font> to $10.86.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447329\" data-linked=\"3D Systems +1% on Nokia integration\" data-tweet=\"$DDD - 3D Systems +1% on Nokia integration https://seekingalpha.com/news/3447329-3d-systemsplus-1-on-nokia-integration?source=tweet\" data-url=\"https://seekingalpha.com/news/3447329-3d-systemsplus-1-on-nokia-integration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447321\" data-ts=\"1554130076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PESI\" target=\"_blank\">PESI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447321-perma-fix-environmentalminus-3-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Perma-Fix Environmental -3% post Q4 results</a></h4><ul><li>Perma-Fix Environmental (<a href='https://seekingalpha.com/symbol/PESI' title='Perma-Fix Environmental Services, Inc.'>PESI</a> <font color=\"red\">-3.1%</font>) reported Q4 revenue decrease of 6.8% Y/Y to $11.47M, due to an unplanned outage of ~2 weeks at Perma-Fix Northwest facility, resulting in impact of ~$800k.</li><li>Segment revenues: Treatment $9.06M (+3.8% Y/Y); and Services $2.67M (-30.7% Y/Y).</li><li>Q4 Gross margin <font color=\"red\">declined by 347 bps</font> to 10.9%.</li><li>Operating loss expanded to $2.1M, compared to $1.2M in Q4 2017.</li><li>Adj. EBITDA was negative $167k, compared to $329k a year ago.</li><li>SG&amp;A expenses were $2.68M a decrease of 3% Y/Y; and R&amp;D $690k (+134.7% Y/Y).</li><li>Company has been awarded several new projects in March that will further increase funded backlog and bolster Services Segment beginning in the second quarter of 2019. Company estimate the total contract value of these awards collectively to be ~$17M through 2019 alone.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447169-perma-fix-environmental-services-reports-q4-results\" target=\"_blank\">Perma-Fix Environmental Services reports Q4 results</a> (April 1).</li></ul><div class=\"tiny-share-widget\" data-id=\"3447321\" data-linked=\"Perma-Fix Environmental -3% post Q4 results\" data-tweet=\"$PESI - Perma-Fix Environmental -3% post Q4 results https://seekingalpha.com/news/3447321-perma-fix-environmentalminus-3-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3447321-perma-fix-environmentalminus-3-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447316\" data-ts=\"1554129907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGN\" target=\"_blank\">NTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447316-neon-therapeutics-up-10-on-neoantigen-vaccine-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neon Therapeutics up 10% on neoantigen vaccine data</a></h4><ul><li>Thinly traded micro cap Neon Therapeutics (<a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics, Inc.'>NTGN</a> <font color=\"green\">+9.9%</font>) is up on average volume following the release of <a href=\"https://seekingalpha.com/pr/17460503-neon-therapeutics-presents-updated-data-ongoing-phase-1b-ntminus-001-clinical-trial-personal\" target=\"_blank\">updated data</a> from a Phase 1b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02897765?id=nt-001&amp;rank=2\" target=\"_blank\">NT-001</a>, evaluating personalized neoantigen vaccine NEO-PV-01, combined with Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"red\">-0.3%</font>) Opdivo (nivolumab), in metastatic melanoma patients. The results were presented at AACR in Atlanta.</li><li>According to R&amp;D chief Richard Gaynor, Ph.D., a new analysis of 36-week data showed that two post-vaccine markers, epitope spread and tumor pathology, \"clearly associate with durable clinical benefit.\"</li><li>52-week results should be available mid-year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447316\" data-linked=\"Neon Therapeutics up 10% on neoantigen vaccine data\" data-tweet=\"$NTGN $NTGN $BMY - Neon Therapeutics up 10% on neoantigen vaccine data https://seekingalpha.com/news/3447316-neon-therapeutics-up-10-on-neoantigen-vaccine-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447316-neon-therapeutics-up-10-on-neoantigen-vaccine-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447320\" data-ts=\"1554129890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447320-discoveryplus-3_7-on-bbc-studios-content-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Discovery +3.7% on BBC Studios content partnership</a></h4><ul>   <li>Discovery (<a href=\"http://seekingalpha.com/symbol/DISCA\" target=\"_blank\">DISCA</a> <font color=\"green\">+3.7%</font>) and BBC Studios have set a long-term content partnership with includes a new video-on-demand service and an agreement on the future of UKTV's channels business in the UK.</li>    <li>The two came to a 10-year agreement on content partnership that makes Discovery the exclusive SVOD home of BBC's natural history programs, including the <i>Planet Earth, Blue Planet</i> and <i>Life</i> series.</li>    <li>Discovery also gets SVOD rights to hundreds of other hours of BBC programming, and will work with BBC to create new landmark factual content. That new service will launch by 2020.</li>    <li>Meanwhile, Discovery will take full ownership of UKTV lifestyle channnels Good Food, Home, and Really. BBC Studios take over the remaining seven channels, along with digital player UKTV Play and the UKTV brand. Discovery has an exiting portfolio of 16 channels in the UK, which include Discovery Channel, TLC, ID, Animal Planet, Eurosport and others.</li>    <li>As part of the UKTV deal, BBC Studios will pay Discovery £173M, which includes £70M of debt currently financed by Discovery.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447320\" data-linked=\"Discovery +3.7% on BBC Studios content partnership\" data-tweet=\"$DISCA - Discovery +3.7% on BBC Studios content partnership https://seekingalpha.com/news/3447320-discoveryplus-3_7-on-bbc-studios-content-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3447320-discoveryplus-3_7-on-bbc-studios-content-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447318\" data-ts=\"1554129580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLT\" target=\"_blank\">TLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447318-bonds-retreat-after-fast-ism-print\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bonds retreat further after fast ISM print</a></h4><ul><li>The 10-year Treasury yield had been tripping along in the 2.60%-2.80% range for several weeks, but then tumbled to about 2.35% in a bit of a buying panic in mid-late March.</li><li>It's up a full eight basis points today to 2.485%, with part of that rise coming <a href=\"https://seekingalpha.com/news/3447288-ism-manufacturing-tops-estimates\" target=\"_blank\">after the March ISM index </a>rebounded from February's two-year low.</li><li>Ignored for now was a pretty <a href=\"https://seekingalpha.com/news/3447201-retail-sales-disappoint\" target=\"_blank\">lame retail sales report</a> for February - ex-autos, sales were down 0.4% vs. estimates for a 0.3% gain. We're talking February though, and the calendar reads April 1.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color=\"red\">-1.2%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a> <font color=\"green\">+1.4%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3447318\" data-linked=\"Bonds retreat further after fast ISM print\" data-tweet=\"$TLT $TBT - Bonds retreat further after fast ISM print https://seekingalpha.com/news/3447318-bonds-retreat-after-fast-ism-print?source=tweet\" data-url=\"https://seekingalpha.com/news/3447318-bonds-retreat-after-fast-ism-print\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447315\" data-ts=\"1554129390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447315-auto-parts-stocks-rev-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto parts stocks rev higher</a></h4><ul> <li>Auto parts stocks rally again after strong earnings from SORL Auto Parts (<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+9%</font>) provide a spark and an upgrade on Adient (<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a> <font color='green'>+10.9%</font>) factors in.</li> <li>Notable gainers include Superior Industries (<a href='https://seekingalpha.com/symbol/SUP' title='Superior Industries International, Inc.'>SUP</a> <font color='green'>+6.9%</font>), Veoneer (<a href='https://seekingalpha.com/symbol/VNE' title='Veoneer, Inc.'>VNE</a> <font color='green'>+7.3%</font>), Delphi Technologies (<a href='https://seekingalpha.com/symbol/DLPH' title='Delphi Technologies PLC'>DLPH</a> <font color='green'>+7.6%</font>), Modine Manufacturing (<a href='https://seekingalpha.com/symbol/MOD' title='Modine Manufacturing Company'>MOD</a> <font color='green'>+5.4%</font>), Visteon (<a href='https://seekingalpha.com/symbol/VC' title='Visteon Corporation'>VC</a> <font color='green'>+5.8%</font>), Lear (<a href='https://seekingalpha.com/symbol/LEA' title='Lear Corporation'>LEA</a> <font color='green'>+4.6%</font>), Autoliv (<a href='https://seekingalpha.com/symbol/ALV' title='Autoliv, Inc.'>ALV</a> <font color='green'>+4.6%</font>), Tenneco (<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a> <font color='green'>+5.2%</font>), Dana (<a href='https://seekingalpha.com/symbol/DAN' title='Dana Incorporated'>DAN</a> <font color='green'>+4.1%</font>), American Axle &amp; Manufacturing (<a href='https://seekingalpha.com/symbol/AXL' title='American Axle & Manufacturing Holdings, Inc.'>AXL</a> <font color='green'>+4.3%</font>), BorgWarner (<a href='https://seekingalpha.com/symbol/BWA' title='BorgWarner Inc.'>BWA</a> <font color='green'>+4.7%</font>), Cooper-Standard (<a href='https://seekingalpha.com/symbol/CPS' title='Cooper-Standard Holdings Inc.'>CPS</a> <font color='green'>+4.9%</font>) and Lydall (<a href='https://seekingalpha.com/symbol/LDL' title='Lydall, Inc.'>LDL</a> <font color='green'>+3.4%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3447121-sorl-autos-q4-results\" target=\"_blank\">More on SORL Auto's Q4 results</a> (April 1)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3447315\" data-linked=\"Auto parts stocks rev higher\" data-tweet=\"$SORL $ADNT $SUP - Auto parts stocks rev higher https://seekingalpha.com/news/3447315-auto-parts-stocks-rev-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3447315-auto-parts-stocks-rev-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447314\" data-ts=\"1554129385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPWK\" target=\"_blank\">UPWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447314-upworkminus-3-on-lockup-expiration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upwork -3% on lockup expiration</a></h4><ul><li>Upwork (NASDAQ:<a href='https://seekingalpha.com/symbol/UPWK' title='Upwork Inc.'>UPWK</a>) <font color=\"red\">drops 2.9%</font> on the expiration of its IPO lockup period.</li><li>The expiration opens up 91.6M shares for trading compared to the 12.3M previously trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447314\" data-linked=\"Upwork -3% on lockup expiration\" data-tweet=\"$UPWK - Upwork -3% on lockup expiration https://seekingalpha.com/news/3447314-upworkminus-3-on-lockup-expiration?source=tweet\" data-url=\"https://seekingalpha.com/news/3447314-upworkminus-3-on-lockup-expiration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447308\" data-ts=\"1554128736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447308-apple-cuts-device-prices-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple cuts device prices in China</a></h4><ul><li>Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color=\"red\">-0.6%</font>) <a href=\"https://www.cnbc.com/2019/04/01/apple-slashes-iphone-prices-in-china-by-as-much-as-5percent.html\" target=\"_blank\">cut its prices</a> for several products on the official online Chinese store by as much as 6%.</li><li>Discounted products include iPhones, iPads, Macs, and AirPods.</li><li>In January, Apple <a href=\"https://seekingalpha.com/news/3420157-apple-cuts-q1-revenue-guidance\" target=\"_blank\">cut its Q1 guidance</a> on weaker than expected iPhone sales \"primarily in Greater China.\" When Q1 <a href=\"https://seekingalpha.com/news/3427231-apple-plus-4-percent-q1-strong-services-downside-guide\" target=\"_blank\">reported</a>, Greater China revenue was down to $13.2B from the prior year's nearly $18B.</li><li>China's new value-added tax cut for manufacturers took effect on April 1, dropping the tax from 16% to 13% and another potential cause for the price drop.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447308\" data-linked=\"Apple cuts device prices in China\" data-tweet=\"$AAPL - Apple cuts device prices in China https://seekingalpha.com/news/3447308-apple-cuts-device-prices-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3447308-apple-cuts-device-prices-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447307\" data-ts=\"1554128668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNRO\" target=\"_blank\">MNRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447307-monro-shakes-off-bear-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monro shakes off bear call</a></h4><ul> <li>Off Wall Street has reportedly <a href=\"https://www.streetinsider.com/Analyst+Comments/Monro+%28MNRO%29+Short+Recommendation+Closed+at+Off+Wall+Street/15320840.html\" target=\"_blank\">closed</a> its short recommendation on Monro (<a href='https://seekingalpha.com/symbol/MNRO' title='Monro, Inc.'>MNRO</a> <font color='green'>+1.4%</font>) with shares up 28% YTD.</li> <li>An improving economy is seen potentially giving Monro more business from lower-skilled workers.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3447307\" data-linked=\"Monro shakes off bear call\" data-tweet=\"$MNRO - Monro shakes off bear call https://seekingalpha.com/news/3447307-monro-shakes-off-bear-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3447307-monro-shakes-off-bear-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447304\" data-ts=\"1554128464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INO\" target=\"_blank\">INO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447304-inovio-completes-enrollment-in-study-of-inominus-5401-inominus-9012-in-brain-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inovio completes enrollment in study of INO-5401 &amp; INO-9012 in brain cancer</a></h4><ul><li>Inovio Pharmaceuticals (<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a> <font color=\"green\">+2.4%</font>) <a href=\"https://seekingalpha.com/pr/17460886-inovio-completes-enrollment-ahead-schedule-immuno-oncology-study-glioblastoma-gbm-inominus\" target=\"_blank\">announces </a>the early completion of enrollment of 52 subjects in a Phase 1/2 clinical trial evaluating T cell-activating immunotherapy INO-5401 and immune activator INO-9012, combined with Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color=\"red\">-0.6%</font>) and Sanofi's (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color=\"green\">+0.3%</font>) PD-1 inhibitor Libtayo (cemiplimab-rwlc), in patients with newly diagnosed glioblastoma.</li><li>The primary endpoint is safety. Secondary endpoints include overall survival and response rate.</li><li>Preliminary data should be available before year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447304\" data-linked=\"Inovio completes enrollment in study of INO-5401 &amp; INO-9012 in brain cancer\" data-tweet=\"$INO $REGN $SNY - Inovio completes enrollment in study of INO-5401 &amp; INO-9012 in brain cancer https://seekingalpha.com/news/3447304-inovio-completes-enrollment-in-study-of-inominus-5401-inominus-9012-in-brain-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3447304-inovio-completes-enrollment-in-study-of-inominus-5401-inominus-9012-in-brain-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447294\" data-ts=\"1554127584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447294-pulmatrix-up-59-on-pulmazole-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix up 59% on Pulmazole deal</a></h4><ul><li>Nano cap Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color=\"green\">+59.1%</font>) is up on increased volume following its <a href=\"https://seekingalpha.com/pr/17461257-pulmatrix-enters-binding-term-sheet-cipla-technologies-llc-development-commercialization\" target=\"_blank\">announced </a>Binding Term Sheet with Cipla Technologies LLC for the development and commercialization of Pulmazole (PUR1900) for the treatment of allergic bronchopulmonary aspergillosis in asthma patients.</li><li>Under the terms of the deal, if formally executed, PULM will receive $22M upfront and will retain the right to receive 50% of the free cash flow from future Pulmazole sales. PULM will be primarily responsible for clinical development while Cipla will be responsible for commercialization.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447294\" data-linked=\"Pulmatrix up 59% on Pulmazole deal\" data-tweet=\"$PULM - Pulmatrix up 59% on Pulmazole deal https://seekingalpha.com/news/3447294-pulmatrix-up-59-on-pulmazole-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3447294-pulmatrix-up-59-on-pulmazole-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447286\" data-ts=\"1554127090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447286-macau-stocks-rally-after-march-ggr-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macau stocks rally after March GGR report</a></h4><ul> <li>Casino stocks are in rally mode after the better-than-anticipated report out of Macau on March gross gaming revenue.</li> <li>Melco Resorts &amp; Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited'>MLCO</a>) is <font color=\"green\">up 5.36%</font>, while Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='green'>+5.1%</font>), Las Vegas Sands (<a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a> <font color='green'>+2.6%</font>), MGM Resorts (<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color='green'>+2.2%</font>) and Studio City International (<a href='https://seekingalpha.com/symbol/MSC' title='Studio City International Holdings Limited'>MSC</a> <font color='green'>+2.7%</font>) are also showing gains.</li> <li>Union Gaming analyst Grant Govertsen says the -0.4% Y/Y drop in March against a tough growth mark of +22% a year ago shows the market is \"resilient\" and is cautiously optimistic that growth can return in May after a -3% GGR decline in April.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447286\" data-linked=\"Macau stocks rally after March GGR report\" data-tweet=\"$MLCO $WYNN $LVS - Macau stocks rally after March GGR report https://seekingalpha.com/news/3447286-macau-stocks-rally-after-march-ggr-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3447286-macau-stocks-rally-after-march-ggr-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447277\" data-ts=\"1554126242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTD\" target=\"_blank\">TTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447277-trade-desk-names-leite-chief-people-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trade Desk names Leite chief people officer</a></h4><ul>   <li>The Trade Desk (<a href=\"http://seekingalpha.com/symbol/TTD\" target=\"_blank\">TTD</a> <font color=\"green\">+1.8%</font>) has appointed Vina Leite as its <a href=\"https://seekingalpha.com/pr/17461251-trade-desk-appoints-vina-leite-chief-people-officer\" target=\"_blank\">chief people officer</a>.</li>    <li>Leite has served as chief people officer at Cylance, recently acquired by BlackBerry, and as chief human resource officer at QLogic.</li>    <li>\u201cVina\u2019s track record of successfully leading organizations through periods of rapid growth will be invaluable as we continue to scale our teams around the world,\u201d says CEO/founder Jeff Green.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447277\" data-linked=\"Trade Desk names Leite chief people officer\" data-tweet=\"$TTD - Trade Desk names Leite chief people officer https://seekingalpha.com/news/3447277-trade-desk-names-leite-chief-people-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3447277-trade-desk-names-leite-chief-people-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447256\" data-ts=\"1554125511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447256-weak-dram-cause-micron-struggles-longbow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak DRAM could cause Micron struggles - Longbow</a></h4><ul><li>Longbow Research says Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) and Western Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) could continue to struggle amid weak DRAM pricing with contract prices in a \"free fall in March,\" accelerating more than expected from the prior month.</li><li>Longbow maintains its view that H2 will be DRAM's bottom and not the recovery.</li><li>The firm is more optimistic on NAND, which turned less negative Y/Y in March, suggesting the bottom in fundamentals was reached. Micron and Western Digital are among the top NAND names.</li><li>Longbow maintains Neutral ratings on MU and WDC.</li><li>Micron shares are <font color=\"green\">up 2.3%</font> and WDC is <font color=\"green\">up 2.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447256\" data-linked=\"Weak DRAM could cause Micron struggles - Longbow\" data-tweet=\"$WDC $MU $MU - Weak DRAM could cause Micron struggles - Longbow https://seekingalpha.com/news/3447256-weak-dram-cause-micron-struggles-longbow?source=tweet\" data-url=\"https://seekingalpha.com/news/3447256-weak-dram-cause-micron-struggles-longbow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447253\" data-ts=\"1554125340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCOR\" target=\"_blank\">SCOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447253-comscoreminus-13_1-after-departures-of-ceo-president\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ComScore -13.1% after departures of CEO, president</a></h4><ul>   <li>ComScore (NASDAQ:<a href='https://seekingalpha.com/symbol/SCOR' title='comScore, Inc.'>SCOR</a>) is <font color=\"red\">13.1% lower</font> premarket after announcing that its CEO and president were each <a href=\"https://seekingalpha.com/pr/17460530-comscore-announces-enhancements-board-directors-senior-management-team-enable-next-phase\" target=\"_blank\">stepping down from their roles</a>.</li>    <li>Bryan Wiener is leaving the CEO's post, and Sarah Hofstetter is exiting the role of president.</li>    <li>Dale Fuller, currently a director, will serve as interim CEO; comScore has launched a search to find a permanent CEO among internal and external candidates. There's no immediate plans to fill Hofstetter's position.</li>    <li>The company also added Irwin Gotlieb, Joanne Bradford and Kathi Love to its board. All the personnel moves are effective today.</li>    <li>ComScore said preliminary Q1 revenue is expected at $100M-$104M; that's light of consensus for $106M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447253\" data-linked=\"ComScore -13.1% after departures of CEO, president\" data-tweet=\"$SCOR - ComScore -13.1% after departures of CEO, president https://seekingalpha.com/news/3447253-comscoreminus-13_1-after-departures-of-ceo-president?source=tweet\" data-url=\"https://seekingalpha.com/news/3447253-comscoreminus-13_1-after-departures-of-ceo-president\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447252\" data-ts=\"1554125213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVM\" target=\"_blank\">CVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447252-cel-sci-up-10-premarket-on-continuation-of-late-stage-study-of-multikine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CEL-SCI up 10% premarket on continuation of late-stage study of Multikine</a></h4><ul><li>Thinly traded micro cap CEL-SCI (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVM' title='CEL-SCI Corporation'>CVM</a>) is up <font color=\"green\">10%</font> premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17459759-cel-sci-reports-recent-data-review-independent-data-monitoring-committee-pivotal-phase-3-head\" target=\"_blank\">announcement </a>that its Phase 3 clinical trial evaluating Multikine (Leukocyte Interleukin, Injection) in newly diagnosed patients with advanced squamous cell carcinoma of the head and neck will continue as planned until the requisite number of events have occurred.</li><li>The action is based on the recommendation from the Independent Data Monitoring Committee that assessed data from all 928 study participants.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447252\" data-linked=\"CEL-SCI up 10% premarket on continuation of late-stage study of Multikine\" data-tweet=\"$CVM - CEL-SCI up 10% premarket on continuation of late-stage study of Multikine https://seekingalpha.com/news/3447252-cel-sci-up-10-premarket-on-continuation-of-late-stage-study-of-multikine?source=tweet\" data-url=\"https://seekingalpha.com/news/3447252-cel-sci-up-10-premarket-on-continuation-of-late-stage-study-of-multikine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447246\" data-ts=\"1554124956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADXS\" target=\"_blank\">ADXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447246-advaxis-up-39-premarket-on-positive-adxs-psa-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advaxis up 39% premarket on positive ADXS-PSA data</a></h4><ul><li>Thinly traded micro cap Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) is up <font color=\"green\">39%</font> premarket on robust volume in response to <a href=\"https://seekingalpha.com/pr/17460933-adxs-psa-combination-keytruda-prolonged-survival-metastatic-castration-resistant-prostate\" target=\"_blank\">updated data</a> from an open-label Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02325557?term=keynote-046&amp;rank=1\" target=\"_blank\">KEYNOTE-046</a>, evaluating immunotherapy candidate ADXS-PSA, combined with Merck's (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a>) Keytruda (pembrolizumab), in 50 patients with metastatic castration-resistant prostate cancer. The results are being presented at AACR in Atlanta.</li><li>At data cutoff, mean overall survival was 21.1 months (n=37). The rate of T cell response against prostate-specific antigen &#40;PSA&#41; was 75%. The rate of antigen spreading was 85%.</li><li>Broader immune stimulation was observed in the combo arm than the ADXS-PSA monotherapy arm.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447246\" data-linked=\"Advaxis up 39% premarket on positive ADXS-PSA data\" data-tweet=\"$ADXS $MRK - Advaxis up 39% premarket on positive ADXS-PSA data https://seekingalpha.com/news/3447246-advaxis-up-39-premarket-on-positive-adxs-psa-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447246-advaxis-up-39-premarket-on-positive-adxs-psa-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447244\" data-ts=\"1554124836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447244-ziop-ttm-and-gevo-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZIOP, TTM and GEVO among premarket gainers</a></h4><ul><li>Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"green\">+40%</font> on positive ADXS-NEO <a href=\"https://seekingalpha.com/news/3447174-advaxis-5-percent-premarket-positive-adxs-neo-data\" target=\"_blank\">data</a>.</li><li>Pulmatrix (NASDAQ:<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/pr/17461257-pulmatrix-enters-binding-term-sheet-cipla-technologies-llc-development-commercialization\" target=\"_blank\">entering</a> into a binding term sheet with Cipla Technologies LLC.</li><li>Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) <font color=\"green\">+19%</font>.</li><li>SORL Auto Parts (NASDAQ:<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>) <font color=\"green\">+15%</font> on <a href=\"https://seekingalpha.com/news/3447119-sorl-auto-misses-0_04-beats-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>iFresh (NASDAQ:<a href='https://seekingalpha.com/symbol/IFMK' title='iFresh Inc.'>IFMK</a>) <font color=\"green\">+14%</font>.</li><li>Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/news/3447062-selecta-discloses-director-purchase-6m-shares\" target=\"_blank\">disclosing</a> director purchase of $6M in shares.</li><li>ZIOPHARM Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) <font color=\"green\">+10%</font> as Ziopharm's Ad-RTS-hIL-12 <a href=\"https://seekingalpha.com/news/3447198-ziopharms-ad-rts-hilminus-12-plus-veledimex-fast-trackd-rgbm-shares-8-percent-premarket\" target=\"_blank\">plus</a> Veledimex Fast Track'd for rGBM.</li><li>Gevo (NASDAQ:<a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a>) <font color=\"green\">+7%</font>.</li><li>Village Farms (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+8%</font> as pure sunfarms <a href=\"https://seekingalpha.com/pr/17460803-village-farms-internationals-pure-sunfarms-doubles-targeted-annual-production-150000\" target=\"_blank\">doubles targeted annual production</a> to 150,000 kgs.</li><li>Tata Motors (NYSE:<a href='https://seekingalpha.com/symbol/TTM' title='Tata Motors Limited'>TTM</a>) <font color=\"green\">+7%</font>.</li><li>TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) <font color=\"green\">+4%</font>.</li><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) <font color=\"green\">+6%</font> on positive umbralisib <a href=\"https://seekingalpha.com/news/3447228-tg-therapeutics-5-percent-premarket-positive-umbralisib-data\" target=\"_blank\">data</a>.</li><li>Veoneer (NYSE:<a href='https://seekingalpha.com/symbol/VNE' title='Veoneer, Inc.'>VNE</a>) <font color=\"green\">+5%</font>.</li><li>ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics, Inc.'>ADMA</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447244\" data-linked=\"ZIOP, TTM and GEVO among premarket gainers\" data-tweet=\"$ADXS $PULM $EVOK - ZIOP, TTM and GEVO among premarket gainers https://seekingalpha.com/news/3447244-ziop-ttm-and-gevo-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447244-ziop-ttm-and-gevo-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447242\" data-ts=\"1554124768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRUS\" target=\"_blank\">CRUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447242-cirrus-logic-drops-on-airpods-exclusion-craig-hallum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cirrus Logic drops on AirPods exclusion - Craig-Hallum</a></h4><ul><li>Craig-Hallum says the <a href=\"https://www.ifixit.com/Teardown/AirPods+2+Teardown/121471\" target=\"_blank\">iFixit teardown</a> confirms that Cirrus Logic's (NASDAQ:<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a>) Adaptive Noise Cancellation or ANC isn't in Apple's new AirPods 2 and says the exclusion could cause shares to drop.</li><li>The low-power codec looks similar to Maxim Integrated's (NASDAQ:<a href='https://seekingalpha.com/symbol/MXIM' title='Maxim Integrated Products, Inc.'>MXIM</a>) previously used codec, which makes it likely Maxim was again the supply winner.</li><li>The firm believes the 27% YTD rally in Cirrus shares was due to investor belief that it was in the AirPods.</li><li>Rating maintained at Hold with a $38 price target.</li><li>Cirrus Logic shares are <font color=\"red\">down 2%</font> to $41.17.</li><li>Maxim shares are <font color=\"green\">up 2.5%</font> to $54.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447242\" data-linked=\"Cirrus Logic drops on AirPods exclusion - Craig-Hallum\" data-tweet=\"$CRUS $CRUS $MXIM - Cirrus Logic drops on AirPods exclusion - Craig-Hallum https://seekingalpha.com/news/3447242-cirrus-logic-drops-on-airpods-exclusion-craig-hallum?source=tweet\" data-url=\"https://seekingalpha.com/news/3447242-cirrus-logic-drops-on-airpods-exclusion-craig-hallum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447239\" data-ts=\"1554124563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELGX\" target=\"_blank\">ELGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447239-endologixplus-7-on-equity-financing-and-debt-restructuring\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endologix +7% on equity financing and debt restructuring</a></h4><ul> <li>Endologix (NASDAQ:<a href='https://seekingalpha.com/symbol/ELGX' title='Endologix, Inc.'>ELGX</a>) has <a href=\"https://seekingalpha.com/pr/17460848-endologix-announces-equity-financing-52-million-debt-restructuring-addressing-2020-maturities\" target=\"_blank\">entered</a> into a definitive agreement to raise ~$52M gross cash proceeds through the issuance of ~7.9M new common stock at a price of       $6.61/share.</li><li>Net proceeds of ~$49M will be used for working capital and general corporate purposes.</li>          <li>In a separate transaction, the Company also entered into an exchange       agreement with two holders of the Company\u2019s 3.25% Senior Convertible       Notes due 2020, pursuant to which these investors       exchanged an aggregate of ~$73M 3.25% Notes plus       accrued interest for ~$67M 5.0% Convertible       Senior Notes due 2024 at the rate of $900 principal       amount of 5.0% Notes for every $1000 principal amount of 3.25% Notes.</li><li>This agreement will replace the Company\u2019s existing 3.25% Convertible       Senior Notes due 2020 for those investors.</li><li>Closing date is April 3.</li>          <li>The Company is reporting preliminary revenue for Q1 ending March 31, of at least $35M. The Company is       reiterating its previously communicated full-year 2019 revenue guidance       of at least $140M.</li><li>Shares are up <font color=\"green\">7%</font> premarket.</li>                    </ul><div class=\"tiny-share-widget\" data-id=\"3447239\" data-linked=\"Endologix +7% on equity financing and debt restructuring\" data-tweet=\"$ELGX - Endologix +7% on equity financing and debt restructuring https://seekingalpha.com/news/3447239-endologixplus-7-on-equity-financing-and-debt-restructuring?source=tweet\" data-url=\"https://seekingalpha.com/news/3447239-endologixplus-7-on-equity-financing-and-debt-restructuring\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447229\" data-ts=\"1554124036\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447229-icon-and-gbr-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ICON and GBR among premarket losers</a></h4><ul><li>Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"red\">-11%</font>.</li><li>New Concept Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447229\" data-linked=\"ICON and GBR among premarket losers\" data-tweet=\"$ICON $GBR - ICON and GBR among premarket losers https://seekingalpha.com/news/3447229-icon-and-gbr-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3447229-icon-and-gbr-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447228\" data-ts=\"1554124016\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447228-tg-therapeutics-up-5-premarket-on-positive-umbralisib-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics up 5% premarket on positive umbralisib data</a></h4><ul><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) is up <font color=\"green\">5%</font> premarket on light volume on the heels of <a href=\"https://seekingalpha.com/pr/17461153-tg-therapeutics-reports-positive-interim-data-unity-nhl-phase-2b-trial-evaluating-umbralisib\" target=\"_blank\">positive preliminary data</a> from a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02793583?term=unity-nhl&amp;rank=1\" target=\"_blank\">UNITY-NHL</a>, evaluating umbralisib, with or without bendamustine and TGR-1202 alone in treatment-naive patients with non-Hodgkin lymphoma. One arm is assessing umbralisib as monotherapy in patients with relapsed or refractory marginal zone lymphoma &#40;MZL&#41;. The results from the MZL group were presented at the AACR conference in Atlanta.</li><li>The overall response rate &#40;ORR&#41; (median follow-up of 12.5 months) was 52% (n=22/42), including eight complete responders.</li><li>The clinical benefit rate (responders + stable cancer), also commonly referred to as the disease control rate &#40;DCR&#41;, was 88% (n=37/42). 86% of treated patients experienced reductions in tumor burden. Median progression-free survival &#40;PFS&#41; has not been reached.</li><li>No new safety signals were observed.</li><li>Final data from the MZL cohort should be available later this year. The company expects to file a U.S. marketing application seeking accelerated approval by year-end.</li><li>Management will host a conference call today at 12:00 pm ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447228\" data-linked=\"TG Therapeutics up 5% premarket on positive umbralisib data\" data-tweet=\"$TGTX - TG Therapeutics up 5% premarket on positive umbralisib data https://seekingalpha.com/news/3447228-tg-therapeutics-up-5-premarket-on-positive-umbralisib-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3447228-tg-therapeutics-up-5-premarket-on-positive-umbralisib-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447224\" data-ts=\"1554123615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFH\" target=\"_blank\">AFH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447224-atlas-financial-delays-10-k-explores-options-sharesminus-5_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlas Financial delays 10-K, explores options; shares -5.3%</a></h4><ul><li>Atlas Financial Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AFH' title='Atlas Financial Holdings, Inc.'>AFH</a>) <font color=\"red\">sinks 5.3%</font> in premarket trading after it<a href=\"https://seekingalpha.com/pr/17461100-atlas-financial-provides-update-form-10-k-filing-strategic-review\" target=\"_blank\"> further delays</a> filing its annual 10-K report and announces it's exploring options, including a potential sale of the company or certain assets and balance sheet strengthening.</li><li>Other potential alternatives include further strengthening of processes and reviewing capital allocation and opportunities.</li><li>The board has formed a special committee of independent directors to examine conclusions and recommendations of this work and provide an update by midyear.</li><li>Expects a further delay in filing its annual form 10-K beyond the additional 15 calendar days provided by its Form 12b-25 filing.</li><li>The company continues to work with its auditors with the objective of filing its 10-K as soon as practicable.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439689-atlas-financial-minus-47-percent-ceo-stresses-increase-reserve-estimates\" target=\"_blank\">Atlas Financial -47% as CEO stresses increase to reserve estimates</a> (March 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3447224\" data-linked=\"Atlas Financial delays 10-K, explores options; shares -5.3%\" data-tweet=\"$AFH - Atlas Financial delays 10-K, explores options; shares -5.3% https://seekingalpha.com/news/3447224-atlas-financial-delays-10-k-explores-options-sharesminus-5_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3447224-atlas-financial-delays-10-k-explores-options-sharesminus-5_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447223\" data-ts=\"1554123557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPSN\" target=\"_blank\">LPSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447223-liveperson-scores-another-strong-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LivePerson scores another strong initiation</a></h4><ul><li>Jefferies initiates LivePerson (NASDAQ:<a href='https://seekingalpha.com/symbol/LPSN' title='LivePerson, Inc.'>LPSN</a>) at Buy with a $36 price target, implying a 24% upside.</li><li>Last month, LivePerson <a href=\"https://seekingalpha.com/news/3445294-piper-starts-liveperson-overweight\" target=\"_blank\">was initiated</a> at Overweight by Piper and Barclays and Outperform by Evercore, which cited the company's position to benefit from broader digital transformation trends.</li><li>LivePerson shares are <font color=\"green\">up 1%</font> pre-market to $29.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447223\" data-linked=\"LivePerson scores another strong initiation\" data-tweet=\"$LPSN - LivePerson scores another strong initiation https://seekingalpha.com/news/3447223-liveperson-scores-another-strong-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3447223-liveperson-scores-another-strong-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447220\" data-ts=\"1554123068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYFT\" target=\"_blank\">LYFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447220-guggenheim-sees-key-issues-for-lyft\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim sees &quot;key issues&quot; for Lyft</a></h4><ul><li>Guggenheim initiates the newly public Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) at Neutral saying it has to \"look too far out with too many big assumptions in order to make a case for the stock.\"</li><li>The firm sees several \"key issues\" including whether Lyft can sustain revenue growth, build investment in growth markets like electric scooters and self-driving vehicles, and drive its valuation higher.</li><li>Guggenheim didn't issue a price target.</li><li>Lyft shares are <font color=\"red\">down 2.9%</font> to $76.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447220\" data-linked=\"Guggenheim sees &quot;key issues&quot; for Lyft\" data-tweet=\"$LYFT - Guggenheim sees &quot;key issues&quot; for Lyft https://seekingalpha.com/news/3447220-guggenheim-sees-key-issues-for-lyft?source=tweet\" data-url=\"https://seekingalpha.com/news/3447220-guggenheim-sees-key-issues-for-lyft\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447213\" data-ts=\"1554122486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATVI\" target=\"_blank\">ATVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447213-wedbush-names-activision-to-best-ideas\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush names Activision to Best Ideas</a></h4><ul><li>Wedbush adds Activision-Blizzard (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc.'>ATVI</a>) to its Best Ideas list with expectations the company will continue to grow and outperform.</li><li>The firm thinks ATVI is well positioned for \"significant outperformance\" this year and \"outsized growth\" next year.</li><li>ATVI's 2019 EPS could approach $2.40 (guidance: $2.10) while $3 is possible for 2020 on a number of potential catalysts including significant growth for <em>Call of Duty</em>, a new<em> World of Warcraft</em> expansion, and substantial King growth.</li><li>ATVI shares are <font color=\"green\">up 2.1%</font> pre-market to $46.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447213\" data-linked=\"Wedbush names Activision to Best Ideas\" data-tweet=\"$ATVI - Wedbush names Activision to Best Ideas https://seekingalpha.com/news/3447213-wedbush-names-activision-to-best-ideas?source=tweet\" data-url=\"https://seekingalpha.com/news/3447213-wedbush-names-activision-to-best-ideas\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447212\" data-ts=\"1554122312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWAV\" target=\"_blank\">SWAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447212-cowen-sees-19-upside-in-astrazeneca-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen sees 19% upside in AstraZeneca in premarket analyst action</a></h4><ul><li>ShockWave Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/SWAV' title='ShockWave Medical, Inc.'>SWAV</a>) initiated with Equal Weight rating at Morgan Stanley. Initiated with Market Perform rating at Wells Fargo. Initiated with Buy rating with a $39 (17% upside) price target at Canaccord Genuity. Initiated with Neutral rating at BofA/Merrill Lynch.</li><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a>) upgraded to Outperform with a $48 (19% upside) price target at Cowen and Company. Shares up <font color=\"green\">3% </font>premarket.</li><li>Healthcare Trust of America (NYSE:<a href='https://seekingalpha.com/symbol/HTA' title='Healthcare Trust of America, Inc.'>HTA</a>) upgraded to Buy with a $33 (15% upside) price target at Jefferies.</li><li>Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) downgraded to Neutral with a $101 (7% upside) price target at Atlantic Equities. Downgraded to Neutral at UBC. Downgraded to Market Perform at William Blair. Shares are down a fraction premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447212\" data-linked=\"Cowen sees 19% upside in AstraZeneca in premarket analyst action\" data-tweet=\"$SWAV $AZN $HTA - Cowen sees 19% upside in AstraZeneca in premarket analyst action https://seekingalpha.com/news/3447212-cowen-sees-19-upside-in-astrazeneca-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3447212-cowen-sees-19-upside-in-astrazeneca-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447198\" data-ts=\"1554121672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447198-ziopharms-ad-rts-hilminus-12-plus-veledimex-fast-trackd-for-rgbm-shares-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm&#39;s Ad-RTS-hIL-12 plus Veledimex Fast Track&#39;d for rGBM; shares up 8% premarket</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17460804-ziopharm-oncology-announces-fda-fast-track-designation-ad-rts-hilminus-12-plus-veledimex\" target=\"_blank\">granted</a> Fast Track Designation for Ziopharm Oncology's (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex, for the treatment of recurrent or progressive glioblastoma multiforme (rGBM) in adults.</li>   <li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li><li>Shares are up <font color=\"green\">8%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3447198\" data-linked=\"Ziopharm&#39;s Ad-RTS-hIL-12 plus Veledimex Fast Track&#39;d for rGBM; shares up 8% premarket\" data-tweet=\"$ZIOP - Ziopharm&#39;s Ad-RTS-hIL-12 plus Veledimex Fast Track&#39;d for rGBM; shares up 8% premarket https://seekingalpha.com/news/3447198-ziopharms-ad-rts-hilminus-12-plus-veledimex-fast-trackd-for-rgbm-shares-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3447198-ziopharms-ad-rts-hilminus-12-plus-veledimex-fast-trackd-for-rgbm-shares-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447194\" data-ts=\"1554121386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447194-tevas-migraine-med-ajovy-okd-in-europe-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva&#39;s migraine med Ajovy OK&#39;d in Europe; shares up 1% premarket</a></h4><ul><li>As expected, the European Commission <a href=\"https://seekingalpha.com/pr/17461050-teva-s-ajovy-receives-eu-approval-offering-patients-first-anti-cgrp-treatment-quarterly\" target=\"_blank\">approves </a>Teva Pharmaceutical Industries' (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) AJOVY (fremanezumab) 225 mg solution for injection in a pre-filled syringe format for the prophylaxis of migraine in adults who have at least four migraine days per month.</li><li>In February, the advisory group CHMP adopted a <a href=\"https://seekingalpha.com/news/3428542-european-advisory-group-backs-tevas-migraine-med-fremenezumab\" target=\"_blank\">positive opinion</a> backing approval.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3447194\" data-linked=\"Teva&#39;s migraine med Ajovy OK&#39;d in Europe; shares up 1% premarket\" data-tweet=\"$TEVA - Teva&#39;s migraine med Ajovy OK&#39;d in Europe; shares up 1% premarket https://seekingalpha.com/news/3447194-tevas-migraine-med-ajovy-okd-in-europe-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3447194-tevas-migraine-med-ajovy-okd-in-europe-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3447185\" data-ts=\"1554120568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APHA\" target=\"_blank\">APHA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3447185-aphria-launches-cannrelief-in-germany\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aphria launches CannRelief in Germany</a></h4><ul> <li>Aphria (NYSE:<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a>) has <a href=\"https://seekingalpha.com/pr/17460582-aphria-introduces-cannrelief-cbd-based-nutraceutical-cosmetics-product-line-german-market\" target=\"_blank\">launched</a> CannRelief, its first CBD-based nutraceutical and cosmetics product line for the German market.</li> <li>A range of skincare and other products, including creams, serums and masks will be introduced under the CannRelief brand in a phased rollout in 2019.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3447185\" data-linked=\"Aphria launches CannRelief in Germany\" data-tweet=\"$APHA - Aphria launches CannRelief in Germany https://seekingalpha.com/news/3447185-aphria-launches-cannrelief-in-germany?source=tweet\" data-url=\"https://seekingalpha.com/news/3447185-aphria-launches-cannrelief-in-germany\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}